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Immun-vermittelte Nierenerkrankungen wie etwa die tubulointerstitielle Nephritis 
bewirken eine tubuläre Dysfunktion und einen chronischen Nierenschaden bis hin 
zum terminalen Nierenversagen. Renale tubuläre Epithelzellen (TECs) sind das 
Hauptziel infiltrierender T-Zellen und interagieren mit diesen durch lösliche Faktoren 
und direkten Zell-Zell-Kontakt. TECs können als Antigen-präsentierende Zellen 
(APCs) fungieren, da sie MHC Klasse I und II Moleküle exprimieren sowie 
kostimulatorische Moleküle, welche unter inflammatorischen Bedingungen exprimiert 
werden. 
 
Die hier dargestellten Untersuchungen zeigen, dass die Stimulation mit den Zytokinen 
IFN-β und IFN-γ die Expression der kostimulatorischen Moleküle ICOS-L, PD-L1 
und CD40 auf TECs in vitro induziert, wohingegen die klassischen 
kostimulatorischen Moleküle B7.1 and B7.2 und andere kostimulatorische Moleküle 
nicht induziert werden. Die Behandlung mit dem Zytokin TGF-β erhöht die 
Expression von CD40 auf TECs, erniedrigt aber die Interferon-induzierte Expression 
von PD-L1. Verglichen mit professionellen APCs wie dendritischen Zellen (DCs) 
haben TECs eine eingeschränkte Expression von kostimulatorischen Molekülen, auch 
unter inflammatorischen Bedingungen. Demzufolge stimulieren TECs T-Zellen nur 
suboptimal, insbesondere im Vergleich mit DCs. PD-L1 exprimiert auf murinen TECs 
schützt diese partiell vor dem Angriff zytotoxischer OVA-Peptid-spezifischer T-
Zellen. Zudem ist die Zytokinsekretion von OVA-spezifischen CD4+ und CD8+ T-
Zellen in vitro reduziert, wenn sie mit TECs die eine hohe Expression von PD-L1 
aufweisen, ko-kultiviert werden. In einem experimentellen Model der autoimmunen 
Nephritis, welches im transgenen RIP-mOVA Mausstamm etabliert wurde, ist PD-L1 
auf TECs in vivo induziert. Demzufolge könnte PD-L1 auch in die Regulation von 
autoreaktiven T-Zell-Antworten in vivo involviert sein. Die PD-L1 Expression auf 
humanen TECs limitiert alloreaktive CD4+ und CD8+ T-Zell-Antworten in vitro. Die 
mRNA Expression von PD-1, PD-L1 und PD-L2 in humanen Biopsieproben von 
verschiedensten Transplantatsabstossungen lässt eine Beteiligung dieses 
koinhibitorischen Signalweges in humaner Nierentransplantation vermuten. 
 
Es lässt sich schlussfolgern, dass PD-L1 exprimiert auf TECs autologe und 
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alloreaktive T-Zell-Antworten in vitro vermindert. Die Expression von PD-L1 auf 
renalen tubulären Epithelzellen könnte daran beteiligt sein, dass Ausmass der 
tubulointerstitiellen Nephritis zu kontrollieren. Ergebnisse dieser Studien erlauben die 
Hypothese zu formulieren, dass dieser Koinhibitorische Signalweg ein therapeutisches 
Ziel sein könnte, durch dessen Aktivierung immun-vermittelte Nierenerkrankungen 






Immune-mediated kidney diseases such as tubulointerstitial nephritis cause renal 
tubular dysfunction and chronic renal failure which may progress to end-stage renal 
disease. Renal tubular epithelial cells (TECs) are the main target of infiltrating T cells 
and interact with these cells through soluble factors and direct cell-cell contact. TECs 
can behave as antigen-presenting cells (APCs) due to their expression of MHC class I 
and II molecules as well as certain co-stimulatory molecules which are induced under 
inflammatory conditions. 
 
The results presented here demonstrate that stimulation with cytokines, e.g. IFN-β and 
IFN-γ induces the expression of the co-stimulatory molecules ICOS-L, PD-L1 and 
CD40 on TECs in vitro, whereas the classical co-stimulatory molecules B7.1 and B7.2 
and other known co-stimulatory molecules are not induced. The treatment with TGF-β 
increases CD40 on murine TECs but decreases the IFN-induced expression of PD-L1 
in vitro. Thus, compared to professional APCs e.g. bone-marrow derived DCs (BM-
DCs) TECs have a limited expression of co-stimulatory molecules even under 
inflammatory conditions. Consequently, TECs only induce suboptimal T cell 
responses in vitro when compared with BM-DCs. Nevertheless, PD-L1 on murine 
TECs partially protects them from the attack of OVA-peptide-specific CD8+ T cells 
and reduces also the cytokine response of OVA-specific CD8+ and CD4+ T cells in 
vitro. PD-L1 may also be involved in regulating auto-reactive T cell responses in vivo 
since it is induced on TECs in an autoimmune model of tubulointerstitial nephritis 
established in RIP-mOVA mice. Furthermore, PD-L1 expression on human TECs 
limits allo-reactive CD4+ and CD8+ T cells responses in vitro and expression of PD-1, 
PD-L1 and PD-L2 in human biopsies of kidney transplant specimens suggests an 
involvement of this co-inhibitory pathway in human kidney transplantation. 
 
In conclusion, PD-L1 on TECs limits auto- and allo-reactive T cell responses in vitro 
and expression of PD-L1 in murine and human kidneys on TECs might be involved in 
controlling the severity of tubulointerstitial nephritis. The findings of these studies 
allow to postulate a new hypotheses regarding the role of this co-inhibitory pathway 
as a possible therapeutic target to inhibit immune-mediated renal diseases upon 
activation of this pathway. 
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The immune system is characterized by a perfect interplay between its innate and 
adaptive parts. This results in a specific defense against pathogens, and in a state of 
tolerance for the body’s own structures. An imbalance triggering an impairment or an 
overshot reaction of the immune system can have fatal consequences. A diminution of 
the immune response leads to a dissemination of pathogens and may cause chronic 
infections whereas an overreaction results in a destruction of the body’s own 
components which manifests as autoimmune disease.  
 
1. The two signal model of T cell activation 
T cells, powerful effectors of the adaptive immune system, recognize their antigen as 
a peptide bound on MHC (major histocompatibility complex) molecules expressed on 
antigen-presenting cells (APCs). In general, a full activation of a naïve T cell and 
thereby a differentiation into an effector cell requires two signals (Figure 1). The first 
signal is the antigen recognition delivered by the interaction of the T cell receptor 
(TCR) and its co-receptors CD4/CD8 with the specific peptide/MHC complex on 
APCs. CD8+ T cells bind to MHC class I molecules and CD4+ T cells to MHC class II 
molecules. The signal 1 alone is not efficient to induce proliferation and 
differentiation of T cells. A co-stimulation signal (signal 2) of the same APC is 
required to fully activate naïve T cells. In the absence of signal 2, T cells fail to 
respond effectively and are rendered anergic. Signal 2 is dependent on signal 1 
because in the absence of the first signal, ligation of co-stimulatory receptors does not 
induce a T cell response.  
 
Figure 1: Two signal model of T cell 
activation 
Taken from Nat Rev Immunol 4:336-347, 
2004 (1).  
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2. Co-stimulatory and co-inhibitory molecules 
The second signal is delivered by co-stimulatory molecules expressed on APCs. Most 
co-signaling molecules are members of the immunoglobulin and tumor-necrosis factor 
(TNF) superfamilies (1). The classical co-stimulation pathway involves the 
immunoglobulin superfamily members B7.1 (CD80) and B7.2 (CD86) on APCs 
binding to their receptor CD28 that is constitutively expressed on T cells. The 
interaction among CD28 and the B7 molecules leads to an activation and the secretion 
of IL-2, enabling clonal expansion of T cells. CD28 is necessary and sufficient to 
induce optimal T cell activation, promotes viability and prevents anergy. Activated T 
cells then express a variety of molecules leading to a prolongation or modification of 
the co-stimulatory signal. For instance CD40L (CD154), a member of the TNF 
superfamily, is upregulated on T cells after signaling through CD28. It binds to the 
receptor CD40 on APCs which leads to a further activation of T cells as well as of 
APCs, resulting in a higher expression of B7 molecules on APCs and consequently in 
an amplification of T cell responses.  
 
CTLA-4 (Cytotoxic T Lymphocyte Antigen-4, CD152) is another receptor that is 
induced on T cells 24-48 h after activation and is also ligated by B7 molecules but 
with a higher avidity than CD28. The interaction between CTLA-4 and B7 molecules 
results in an inhibitory signal delivered to naïve and primed T cells, making them less 
susceptible to the co-stimulation by APCs and reduces the production of IL-2 as well. 
Due to the ligation of CTLA-4 this co-inhibitory signal results in the termination of 
the clonal expansion of T cells (2-4). 
 
Co-stimulatory and co-inhibitory molecules on APCs regulate the strength, course and 
duration of T cell responses. The balance of stimulatory and inhibitory signals is 
crucial to achieve protective immune responses while maintaining immunological 
tolerance and preventing autoimmunity. Due to this fine regulation of T cell responses 
co-stimulatory pathways are a target of therapeutic intervention. Prevention of acute 
rejection and optimal tolerance have been achieved in nonhuman primate models of 
kidney transplantation using anti-CD154 (anti-CD40L) (5). Therapeutic inhibition of 
the CD28 pathway is performed with the CTLA-4Ig molecules Abatacept and 
Belatacept that bind to B7 molecules on APCs such as dendritic cells (DCs), thereby 
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blocking their interaction with CD28 on T cells and inhibiting T cell activation and 
proliferation. Furthermore, CTLA-4Ig induces reverse signaling by binding to B7 
molecules on DCs. This leads to an induction of the enzyme indoleamine 2,3-
dioxygenase (IDO) which results in depletion of tryptophan and consequently in 
inhibition of T cell proliferation (1, 6). Abatacept is approved for the treatment of 
patients with rheumatoid arthritis and Belatacept is being investigated in clinical trials 
for renal transplantation (7).  
 
Novel co-stimulatory and co-inhibitory molecules have been discovered during the 
last decade, including the new B7 family members PD-L1 and PD-L2, ICOS-L, B7-
H3 and B7-H4 (Table 1). The PD-1/PD-L pathway will be discussed in detail in the 
next paragraph. The ICOS/ICOS-L pathway is important for stimulating effector T 
cell responses and T cell-dependent B cell responses, but is also involved in T cell 
tolerance (8). The role of B7-H3 in regulating T cell responses is contradictory. Some 
studies suggest a co-stimulatory and others a co-inhibitory function which may 
depend on different receptors for B7-H3 (9). B7-H4 is a negative regulator of T cell 
responses and expression of B7-H4 on tumors suggests a role in evasion of tumor 
immunity (8). Most of these molecules are constitutively expressed on professional 
APCs (DCs, macrophages, B cells) as well as on non-lymphoid organs, providing new 
insights into the regulation of T cell activation and tolerance in peripheral tissues. 
 
Table 1: Overview of the B7 family members 
Co-stimulatory/ 
Co-inhibitory molecule Synonym 
CD 
nomenclature Binding partner 
B7.1  CD80 CD28, CTLA-4, PD-L1
B7.2  CD86 CD28, CTLA-4 
B7-H2/B7h ICOS-L, B7RP-1 CD275 ICOS 
B7-H1 PD-L1 CD274 PD-1, B7.1 
B7-DC PD-L2 CD273 PD-1 
B7-H3  CD276 TLT-2, n.d. 
B7-H4 B7x, B7S1, VTCN1 ? BTLA-4 
 
CTLA-4: Cytotoxic T lymphocyte attenuator; PD-1: Programmed Death 1; ICOS: 
Inducible Costimulator; TLT-2: (TREM)-like transcript 2; VTCN1: V-set domain 
containing T cell activation inhibitor 1; BTLA-4: B and T lymphocyte associated protein 
4; n.d. not determind 
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3. The PD-1/PD-L pathways - their expression and function  
The Programmed Death 1 (PD-1, also called CD279) molecule and its ligands PD-L1 
(also named B7-H1 and CD274) and PD-L2 (also called B7-DC and CD273) belong 
to the B7/CD28 family and are important pathways delivering inhibitory signals to T 
cells. PD-1 has been discovered in 1992 in a T cell hybridoma undergoing cell death 
(10). The ligands PD-L1 and PD-L2 have been identified nearly 10 years later in 2000 
and 2001, respectively (11, 12).  
 
3.1. Distribution and structure of PD-1, PD-L1 and PD-L2 
 
PD-1 expression has been found on T and B cells, NK cells, activated monocytes and 
DCs. PD-1 is weakly expressed on resting T cells but is induced after ligation of the 
TCR. PD-1 is encoded by the Pdcd1 gene on chromosome 1 in mice and on 
chromosome 2 in humans. It is a 50-55 kDa type I monomeric receptor exhibiting one 
immunoglobulin variable (IgV)-like domain and an immunoglobulin constant (IgC)-
like domain in the extracellular portion, a transmembrane region and an intracellular 
domain composed of an immunoreceptor tyrosine-based inhibitory motif (ITIM) and 
an immunoreceptor tyrosine switched motif (ITSM). Engagement of PD-1 leads to 
phosphorylation of its two intracellular tyrosines, followed by a recruitment of the 
phosphatase SHP-2 (Src homology 2-domain-containing tyrosine phosphatase) to the 
ITIM and ITSM motifs. The activation of the phosphatase blocks the signaling of the 
PI3K pathways and downstream of Akt resulting in inhibition of early antigen 
receptor (TCR, BCR) signaling (Figure 2). Therefore, PD-1 needs to be in proximity 
to the antigen receptor. Ligation of PD-1 on T cells by its two ligands decreases the 
induction of certain cytokines including IFN-γ, TNF-α and IL-2 as well as the cell 
survival factor Bcl-xL. This reduction can be overcome by co-stimulation through 
CD28 or IL-2 (Figure 2). PD-1 typically has greater effects on cytokine production 
than on cellular proliferation (1, 13).  
 
 7
  INTRODUCTION 
 
Figure 2: Ligation of PD-1 on T cells inhibits TCR signaling. Taken from Ann 
Rev Immunol 26: 677-704, 2008 (13).  
 
PD-L1 is a membrane protein which consists of one IgV-like domain and one IgC-like 
domain, a transmembrane part and a short intracellular domain. PD-L1 is encoded by 
the Cd274 gene on mouse chromosome 19 and on chromosome 9 of humans. PD-L1 
is constitutively expressed on mouse T and B cells, DCs, macrophages, mesenchymal 
stem cells and can be found on a variety of nonhematopoetic and parenchymal cells 
including lung, liver, heart, brain, placenta and kidney. PD-L1 is upregulated on 
activated T and B cells and on a wide range of cells after stimulation with type I and 
II interferons (11, 13).  
 
PD-L2 is also a transmembrane protein exhibiting the same structure as PD-L1 but 
different lengths of the cytoplasmic domain have been reported. PD-L2 is encoded by 
the Pdcd1lg2 gene adjacent to Cd274 but its expression is much more restricted 
compared to the PD-L1 expression. PD-L2 can be induced on DCs, monocytes and 
macrophages and it is also found on lung, vascular endothelial cells and placenta (12, 
13). The distinct expression pattern of PD-L1 and PD-L2 suggest broad roles for PD-
L1 in peripheral organs and selective roles for PD-L2 in lymphoid organs. 
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3.2. The role of the PD-1/PD-L1 pathway in tolerance and autoimmunity 
 
An inhibitory role on the immune system of the PD-1/PD-L pathway on T cell 
activation has first been identified in Pdcd1-/- C57BL/6 and Pdcd1-/- Balb/c mice that 
develop mild glomerulonephritis and dilated cardiomyopathy, respectively (14, 15). 
These findings have suggested that the PD-1/PD-L pathway has a critical role in the 
induction and maintenance of tolerance and therefore in the control of autoimmunity. 
PD-L1 and PD-L2 expressed in the thymus interact with PD-1 expressing immature 
thymocytes and influence the positive and negative selection of T cells, thereby 
contributing to central tolerance (13).  
 
The broad expression of PD-L1 on parenchymal tissues and immune-privileged sites 
such as placenta and eyes has further suggested an involvement in the regulation of 
peripheral tolerance. Sharpe et al. propose the following model (Figure 3) how the 
PD-1/PD-L1 pathway may control peripheral tolerance and autoimmunity:  
 
 
Figure 3: Control of autoimmunity by the PD-1/PD-L pathway. Adapted from Nat 
Immunol 8: 239-245, 2007 (16).  
 
1) The presentation of self-antigens by immature DCs expressing PD-L1/L2 limits the 
expansion of self-reactive T cells and induces tolerance. In contrast, 2) activated DCs 
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may trigger the proliferation of self-reactive T cells which then home to the tissue 
expressing the self-antigen. 3) The extravasation of the T cells may be limited by PD-
L1 expression on vascular endothelial cells. Furthermore, the expression of PD-L1 
may protect the tissue from the attack of self-reactive T cells whereas tissue cells that 
do not express PD-L1 are destroyed (16). 
 
Various studies support the critical role of the PD-1/PD-L pathway in regulating 
tolerance. Expression of PD-L1 in the placenta increases at the beginning of the 
second trimester and promotes fetal-maternal tolerance. The inhibition of PD-L1 with 
antibodies has increased the abortion rate of allogeneic fetuses and has been 
associated with increased T cell infiltration into the placenta (17, 18). Intestinal 
tolerance to self-antigens can be converted to autoimmune enteritis when the PD-
1/PD-L pathway is blocked (19). Animal models of autoimmune diseases including 
diabetes and experimental autoimmune encephalomyelitis (EAE) have been 
exacerbated after blockade of the PD-1/PD-L1 pathway (20-22). A role for the PD-1 
pathway in human autoimmune diseases has been suggested by polymorphisms in the 
Pdcd1 gene that have been associated with systemic lupus erythematosus (SLE), type 
1 diabetes, rheumatoid arthritis, Grave’s disease and multiple sclerosis (23). 
 
Allograft tolerance is also partially mediated by PD-1/PD-L interactions (24, 25). PD-
1 and PD-L1 are upregulated on allo-reactive T cells. Blockade of PD-L1, but not PD-
L2, has accelerated rejection of MHC class II mismatched skin grafts in mice (26). 
This has also been shown for experimental models of heart, corneal and pancreas 
transplantation (27-29). Graft-versus-host disease (GVHD) lethality is accelerated by 
an IFN-γ-dependent mechanism in a murine model of acute GVHD when PD-1 
engagement is prevented (30). It has been demonstrated in human liver transplantation 
that graft-versus-host-reactive CD8+ T cells express high levels of PD-1 and that 
blockade of PD-L1 on host-derived cells enhances the allo-reactivity of these CD8+ T 
cells in vitro (31). 
 
A functional PD-1/PD-L pathway is beneficial in limiting expansion of self-and allo-
reactive T cells and thereby prevents autoimmunity and allograft rejection. On the 
other hand increased expression of this pathway has also been found in many human 
cancers and infectious diseases with detrimental effect.  
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3.3. The role of the PD-1/PD-L1 pathway in tumor escape and infections 
 
Tumor cells escape the immune response by expressing PD-1 ligands. An increased 
expression of PD-L1 has been found on human cancer tissues of lung, ovary, bladder, 
breast, stomach, colon, pancreas, liver, urothelial cells and kidney. For many of them, 
a strong correlation of PD-L1 expression on tumor cells has been associated with a 
poor prognosis (32-34). Thompson et al. have reported that patients with high tumor 
and/or lymphocyte PD-L1 are 4.5 times more likely to die from renal cell carcinoma 
than patients exhibiting low levels of PD-L1. Furthermore, the expression of PD-1 on 
tumor infiltrating immune cells has also been associated with poor outcome in these 
patients suffering from renal cell carcinoma (35, 36). A new mechanism has linked 
the loss of the tumor suppressor PTEN (phosphatase and tensin homolog) with a 
posttranscriptional increase of PD-L1 in human glioma. Glioma cell lines that do not 
express PTEN have been resistant to the cytolytic activity of tumor-specific T cells 
and the blockade of PD-1 partially restored the lytic activity (32, 37).  
 
PD-1 and its ligands also have important roles in regulating immune defenses against 
pathogens that cause acute and chronic infections. Pdcd1-/- mice clear an adenovirus 
infection more rapidly but develop more severe hepatocellular injury than wild type 
mice suggesting that the PD-1/PD-L pathway limits the detrimental consequences of 
overshooting virus-specific effector T cells (13, 38). Viruses that cause chronic 
infections are using the PD-1/PD-L pathway to evade the immune system (13). Barber 
et al. have shown that CD8+ T cells of mice that have been chronically infected with 
LCMV expressed high levels of PD-1 and have been exhausted. Blockade of PD-1 
and PD-L1 in vivo has reduced the viral load due to a restored ability of CD8+ T cells 
to proliferate, secrete cytokines and kill infected cells (39). CD8+ T cell exhaustion 
due to PD-1 expression has also been demonstrated in human chronic viral infections 
including HIV, HBV and HCV and has even been associated with disease progression 
(40-43). A key role for the PD-1/PD-L pathway has also been shown for chronic 
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3.4. Reverse signaling of PD-L1 
 
Some of the studies have demonstrated that blockade of PD-L1 has not the same 
effect as inhibition of PD-1, suggesting the existence of another receptor for PD-L1. 
Recently, B7.1 has been identified as another binding partner for PD-L1 identifying 
reverse signaling through PD-L1 and B7.1 (13, 44, 45). Both can interact through 
their IgV-like domains. B7.1/PD-L1 specific interactions can induce inhibitory signals 
for T cells. The ligation of PD-L1 on CD4+ T cells by B7.1 or ligation of B7.1 on 
CD4+ T cells by PD-L1 delivers an inhibitory signal in terms of decreased 
proliferation and impaired cytokine production. PD-L1 and B7.1 are both expressed 
on T and B cells, DCs and macrophages suggesting a bidirectional interaction 
between B7.1 and PD-L1. PD-L1 on non-hematopoietic cells may interact with PD-1 
as well as with B7.1 on T cells. Reverse signaling of PD-L1 has been also shown on 
tumor cells receiving survival signals after engagement of PD-L1 by PD-1 expressing 
immune cells (46). 
 
3.5. Therapeutic modulation of the PD-1/PD-L1 pathway 
 
The broad involvement of the PD-1/PD-L pathways in regulating immune responses 
provides therapeutic opportunities. PD-1/PD-L antagonists may be beneficial in 
augmenting anti-microbial and anti-tumor immunity (13, 32). A fully humanized anti-
PD-1 monoclonal antibody has been developed and is in Phase 1 clinical trials for 
cancer. Thus far this antibody has been shown to be safe and well tolerated in patients 
with advanced hematologic malignancies (47). Furthermore, blockade of PD-1 has 
enhanced the expansion and functional capacity of human melanoma antigen-specific 
cytotoxic T cells in vitro (48). PD-1/PD-L agonists that suppress adverse immune 
responses may be useful to treat autoimmune diseases and transplant rejection. 
Enhancement of the PD-1/PD-L pathway in humans could also be achieved by 
treatment with IFN-β that is used for the treatment of multiple sclerosis (MS) and has 
induced expression of PD-L1 and PD-L2 on monocytes and CD4+ T cells of patients 
with MS (49, 50).  
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4. Immune-mediated tubulointerstitial renal diseases 
Immune-mediated tubulointerstitial renal diseases represent an important but 
heterogeneous class of kidney pathologies. Typical diseases include primary acute and 
chronic tubulointerstitial nephritis (TIN), and secondary interstitial nephritides which 
are seen in the context of systemic diseases such as sarcoidosis, Wegener’s disease, 
systemic lupus erythematosus (SLE), or Sjögren’s syndrome. 
 
Primary acute TIN is often due to “allergic” immune reactions against drugs, mostly 
antibiotics, diuretics and non-steroidal anti-inflammatory drugs, or it is caused by 
infections with bacteria or viruses including streptococci, staphylococci, EBV or HIV 
(51). Furthermore, the main feature of acute cellular transplant rejection represents 
tubulitis (Figure 4A) – the invasion of the tubular epithelium by infiltrating T cells 




Figure 4: (A) Renal biopsy of a patient with acute allergic interstitial nephritis 
secondary to ingestion of non-steroidal inflammatory drugs. There is interstitial 
edema and a mixed cellular infiltrate which contains mononuclear cells, 
leukocytes and eosinophils (arrowheads). There is also evidence of tubulitis (T) 
with foci of tubular epithelial cell necrosis (orig. magnification x300, H&E stain). 
Picture and legend taken from Kidney Int 54:313-327, 1998 (51). (B) Chronic 
interstitial nephritis shows interstitial fibrosis and a mixed inflammatory infiltrate 
composed of lymphocytes, plasma cells, and eosinophils (orig. magnification 
x28.). Picture and legend taken from Am J Kidney Dis 49: E7-E10, 2007 (53). 
 
In acute interstitial nephritis, the tubular damage leads to renal tubular dysfunction, 
with or without renal failure. Regardless of the severity of the damage to the tubular 
epithelium, the renal dysfunction is generally reversible. Conversely, chronic 
tubulointerstitial nephritis is characterized by interstitial scarring, fibrosis (Figure 4 
B), and tubular atrophy, resulting in progressive chronic renal failure and end-stage 
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renal disease. 
 
Cellular immunity is the principal effector mechanism of tubulointerstitial renal 
injury. Various types of immune cells including neutrophils, eosinophils, 
macrophages, DCs, B cells, NK cells and activated T cells are found in the 
tubulointerstitial compartment of patients with TIN and renal allograft rejection 
(RAR). These cells contribute extensively to tissue damage and progressive renal 
failure via their respective intrinsic mechanisms.  
 
Activated T cells are the predominant effector cells in tubulointerstitial renal injury 
(54, 55). Infiltrating CD4+ and CD8+ T cells are found in abundance in most 
tubulointerstitial disease processes, including TIN and RAR, especially in acute T 
cell-mediated rejection. Their functional role in nephritic inflammation may be 
exerted via interaction with other infiltrating and/or resident cells such as 
macrophages and DCs and/or via their direct contact with renal tubular epithelial cells 
(TECs) which present auto- or foreign antigens to specific T cells. For example, in 
biopsies of drug-induced acute interstitial nephritis drug-specific T cells were found in 
the T cell infiltrate, suggesting that the drug was presented in the kidney in an 
immunogenic way, thereby triggering an immune response or reactivating 
immigrating cells (56).  
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5. Renal TECs are “non-professional” APCs  
Renal proximal tubular epithelial cells (TECs) are the main target of infiltrating 
leukocytes during immune-mediated kidney diseases. There is an intensive cross-talk 
between resident TECs and infiltrating cells, either by soluble factors or by direct 
contact. TECs can be directly involved in renal parenchymal immune responses by 
acting as APCs and target cells of T cells (Figure 5). 
 
After stimulation with leukocyte-derived cytokines e.g. IL-1, IL-17, TNF-α or IFN-γ, 
TECs become activated and release a broad variety of cytokines and chemokines, 
including IL-6, IL-15, IL-18, TNF-α, TGF-β, IL-8, MCP-1, MIP-1α and RANTES. 
This has been shown in cell culture experiments but also in renal graft biopsies with 
rejection (57). External stress factors e.g. protein overload, active peptides or ischemia 
also trigger cytokine and chemokine production by TECs. The cytokine secretion by 
TECs influences T cells and monocytes in terms of proliferation, survival and serves 
as chemoattractant to recruit further leukocytes. The cytokines also affect TECs in an 
autocrine manner, for example TGF-β can lead to transdifferentiation of TECs into 
myofibroblasts and overproduction of matrix components by TECs results in fibrosis 
and consequently in loss of kidney or graft function (58). 
 
As a response to immune stimuli, TECs upregulate the expression of MHC molecules, 
adhesion molecules, co-stimulatory and co-inhibitory molecules favoring a direct 
contact with leukocytes and modulating T cell responses. Like most cells of the body, 
TECs constitutively express MHC class I molecules but stimulation with IL-1, TNF-α 
and IFN-γ further increases MHC class I molecules and also induces MHC class II 
expression (59, 60). Therefore, TECs can behave as APCs presenting peptides of self- 
and foreign origin to CD4+ and CD8+ T cells. Adhesion molecules including 
intercellular adhesion molecule-1 (ICAM-1), lymphocyte function-associated antigen-
3 (LFA-3), vascular cell adhesion molecule 1 (VCAM-1) are also induced on TECs 
after cytokine stimulation and can stabilize the interaction among TECs and 
lymphocytes. The classical co-stimulatory molecules B7.1 and B7.2 are not expressed 
on TEC and can not be induced upon stimulation with IFN-γ, TNF-α or LPS 
suggesting that TECs are unable to fully activate T cells. However, treatment with IL-
17, IFN-β, IFN-γ and TNF-α enhances CD40 expression on TECs in vitro indicating 
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an involvement of the CD40-CD40L pathway in the interaction between TECs and T 
cells (57). The expression of ICOS-L has been found in normal human kidneys and in 
renal allograft biopsies with rejection and interstitial nephritis, particularly in the areas 
of mononuclear cell infiltration suggesting a regulation of T cell activation by the 
ICOS/ICOS-L pathway. ICOS-L can be upregulated by interferon treatment on human 
and murine TECs in vitro and inhibits T cell responses (61, 62) in terms of IL-2 and 
IFN-γ production. In a mouse model of kidney allotransplantation, the blockade of 
ICOS has resulted in continuous inflammatory processes with progressive tissue 
damage and graft failure (63). Thus, this pathway may be one of the mechanism to 
inhibit immune-mediated TEC injury (57, 64). 
 
PD-L1 and PD-L2 expression has also been found on human and murine TECs, 
especially after IFN-γ stimulation in vitro (65, 66). In a mouse model of renal 
allografts, PD-L1 is expressed on proximal and distal tubules in rejected transplants 
whereas staining of normal kidneys and isografts is negative. Furthermore, PD-L1 on 
TECs has inhibited IL-2, IL-4 and IFN-γ production of CD4+ T cells in TEC-T cell 
co-culture experiments (67). These data suggest that PD-L1 on TECs is also involved 
in regulating immune responses in the kidney.  
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Figure 5: Complex interaction between TECs and infiltrating immune cells. Activated T 
cells are attracted into cortical tubules probably via chemokines from tubular cells, made in 
response to cytokines from inflammatory cells. T cells enter between TECs (tubulitis) and 
cytotoxic T cells may cause apoptosis by releasing cytolytic granules containing granzymes 
and perforin or by FasL/Fas interaction. IFN-γ secretion by CD8+ and CD4+ T cells may 
induce expression of MHC class I and II, CD40, ICOS-L and PD-L1 on TECs and may 
modulate T cell responses. Chronic exposure of TECs to TGF-β released by macrophages or 
TECs themselves may lead to epithelial-mesenchymal transition of TECs. These cells are 
characterized by α-smooth muscle actin (αSMA) and loss of E-cadherin expression and may 
infiltrate the interstitium and contribute to fibrosis. Resident/infiltrated DCs or macrophages 
may also interact with infiltrating T cells as well as with TECs either directly or by soluble 
mediators. 





The role of the PD-1/PD-L pathway in immune-mediated renal diseases has not been 
described yet. First studies have shown that PD-L1 is expressed on renal tubular 
epithelial cells in vitro and in vivo and therefore suggest an involvement in the 
regulation of immune responses in the kidney. Whether PD-L1 and/or PD-L2 on renal 
tubular epithelial cells can regulate CD4+ and CD8+ T cell responses is largely 
unknown. 
 
The aim of this dissertation has been a further description and identification of the 
role of the PD-1/PD-L pathway on renal tubular epithelial cells in regulating T cell 
responses. The interaction between TECs and T cells has been investigated using in 
vitro co-culture experiments of TECs and T cells of both mouse and human origin. 
Furthermore, an experimental model of tubulointerstitial nephritis has been 
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 Introduction
 Renal proximal tubular epithelial cells (TEC) are a 
major target of renal damage during immune-mediated 
kidney diseases. Under nephritic conditions, inflamma-
tory cytokines are produced either by infiltrating im-
mune cells or by activated TEC themselves. Intrarenal 
inflammatory cytokine stimulation promotes the upreg-
ulation of MHC class I and class II molecules on the 
 surface of renal TEC, allowing TEC to act as ‘non-profes-
sional’ antigen-presenting cells (APC) to activate anti-
gen-specific CD4 and CD8 T cells  [1–3] . As a conse-
quence, TEC may become direct targets of CD8 cytotox-
ic T lymphocytes (CTL) causing tubular damage and loss 
of renal function.
 It has been well established that in addition to the first 
signal (the binding between MHC/peptide complex and T 
cell receptor), costimulatory or coinhibitory molecules 
provide the second signal that is essential in determining 
the magnitude of T cell activation or T cell tolerance  [4, 5] . 
Besides the well-known classical costimulatory pathways 
B7/CD28, CD40/CD40L and the coinhibitory pathway B7/
CTLA-4, several novel costimulatory molecules have been 
discovered during the last decade, including new B7 fam-
ily members PD-L1 and PD-L2 (ligands 1 and 2 for the 
programmed death-1, PD-1), also known as B7-H1 and B7-
DC, respectively, ICOS-L (the ligand for the inducible co-
stimulator, ICOS), also known as B7RP-1, B7-H3, B7-H4 
and new TNFR family members OX40L, 4-1BBL, CD70 
and CD30L  [4, 5] . Most of these molecules are constitu-
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 Abstract
 Background/Aims: MHC molecules are upregulated on re-
nal proximal tubular epithelial cells (TEC) under inflamma-
tory conditions. This allows TEC to act as ‘non-professional’ 
antigen-presenting cells (APC). The aim of this study was to 
compare the costimulatory molecule expression pattern 
and the T cell activation capacity between renal TEC and 
professional APC, e.g. bone marrow-derived dendritic cells 
(BM-DC).  Methods: Flow cytometry analysis was used to 
study the costimulatory molecule surface expression on TEC 
or BM-DC. Ovalbumin-specific CD4 and CD8 T cell activation 
induced by TEC or BM-DC was compared, in terms of T cell 
proliferation, cytokine production and CTL activity.  Results: 
TEC did not constitutively express significant amounts of co-
stimulatory molecules. Stimulation of TEC with IFN-  or IFN-
  , but not other tested cytokines, enhanced the expression 
of PD-L1, ICOS-L and CD40. Compared to BM-DC, TEC only 
induced suboptimal T cell activation. Blockade of PD-L1 on 
both APC strongly increased T cell activity. Furthermore, 
high PD-L1-expressing TEC were more resistant to the cy-
tolysis by CTL.  Conclusion: The low costimulatory molecule 
expression may explain the suboptimal T cell activation by 
TEC. The IFN-upregulated negative costimulatory molecule 
PD-L1 on TEC may play a protective role to limit tissue injury 
during renal parenchymal immune responses.
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tively expressed on professional APC such as macrophages 
and dendritic cells and can be further upregulated when 
stimulated with pro-inflammatory cytokines. These nov-
el costimulatory/coinhibitory molecules may provide an 
alternative secondary signal for the control of T cell re-
sponses under immunopathologic conditions   and   for the 
maintenance of peripheral tolerance  [4–7] .
 A prominent upregulation of the costimulatory mol-
ecules PD-L1 and ICOS-L on renal TEC with IFN-  stim-
ulation has been described by our group and others  [8–
11] . Recently, we observed that the type I IFN, IFN-  , was 
also able to induce PD-L1 upregulation on renal TEC  [12] . 
However, a full understanding of the expression pattern 
of costimulatory molecules on renal TEC and/or their re-
sponse profile to inflammatory cytokines has not yet 
been elucidated. Furthermore, how the costimulatory 
signal (signal 2) influences or impacts the T cell activa-
tion capacity of TEC is not fully clear so far. In this study, 
we compared the expression profile of all known B7 and 
TNFR family costimulatory molecules under non-in-
flammatory conditions between murine renal TEC pri-
mary cultures and bone marrow-derived dendritic cells 
(BM-DC). We also examined the costimulatory molecule 
expression on TEC upon stimulation with a large range 
of selected inflammatory cytokines which can be detect-
ed in the inflamed kidney. The capacity of presenting 
MHC class I- and class II-restricted ovalbumin (OVA) 
antigens by renal TEC was then investigated and com-
pared with professional APC, e.g. BM-DC.
 Materials and Methods
 General Reagents
 Cell culture reagents were obtained from Invitrogen (Gai-
thersburg, Md., USA) and Sigma (St. Louis, Mo., USA). All recom-
binant mouse cytokines used in this study were purchased from 
R&D Systems (Oxford, UK). All anti-mouse monoclonal antibod-
ies (mAbs) were bought from eBioscience (San Diego, Calif., USA) 
if not specified. Chicken OVA protein was purchased from Sigma 
and the H-2K b -restricted OVA peptide 257–264 (OVA 257–264 ) was 
received from Proimmune (London, UK). An H-2K b -restricted 
  -galactosidase peptide 497–504 (  -Gal 497–504 ) was used as a neg-
ative control. Mouse CD8a (Ly-2), CD4 (L3T4) and CD11c (N418) 
MACS microbeads were obtained from Miltenyi Biotec (Bergisch 
Gladbach, Germany).
 Animals
 TCR transgenic OT-1 mice  [13] were obtained from Jackson 
Laboratories (Bar Harbor, Me., USA). C57BL/6 (B6) mice were 
purchased from Harlan (Horst, Netherlands). All animals were 
used at 8–16 weeks of age. The study protocol was approved by the 
regulatory commission for animal studies of the Canton of Zur-
ich, Switzerland.
 Generation of Primary Renal TEC, BM-DC
 Primary cultures of murine renal proximal TEC were pre-
pared and cultured as described previously  [14] . BM-DC were pre-
pared and matured with lipopolysaccharide (LPS, Sigma, 10   g/
ml) for 2 days as described elsewhere  [15] . The matured BM-DC 
were purified using mouse CD11c MACS microbeads before be-
ing used in experiments. All cells were maintained at 37  °  C with 
5% CO 2 .
 Isolation and Activation of OVA-Specific OT-1 CD8 T Cells
 H-2K b -restricted OVA 257–264 -specific CD8 OT-1 cells were 
isolated from spleen and lymph nodes of naïve OT-1 mice with 
mouse CD8a MACS microbeads. The freshly isolated OT-1 CD8 
T cells were either used immediately for antigen presentation as-
says, or activated in vitro using B6 splenocytes pulsed with 0.1 
  g/ml of OVA 257–264  peptide and incubated in T cell medium 
(DMEM supplemented with 5   M 2-mercaptoethanol, 1% HEPES, 
1,000 U/ml penicillin, 100   g/ml streptomycin and 10% FBS). Af-
ter 5–6 days of stimulation, activated OT-1 CTL were used for 
CTL assays.
 Immunization
 To obtain OVA protein-specific CD4 T cells, B6 mice were im-
munized subcutaneously with 100   g of OVA protein in PBS 
emulsified in Incomplete Freund’s Adjuvant (IFA) at the base of 
the tail. Two weeks later, CD4 T cells were isolated from the drain-
ing lymph nodes and spleens using mouse CD4 MACS micro-
beads and used immediately for T cell assays.
 Flow Cytometric Analysis
 B6 primary renal TEC were harvested by light trypsinisation. 
Before staining with primary antibodies, BM-DC were pre-incu-
bated with anti-mouse CD16/32 mAb for 15 min to block FcR 
binding. TEC or BM-DC were then incubated with specific pri-
mary mAbs for 45 min. Cells were then washed and incubated 
with the appropriate FITC-conjugated secondary antibody (Ab) 
for an additional 30 min and analyzed using the FACScan flow 
cytometer and Cell Quest TM  software (Becton Dickinson).
 OT-1 CD8 T Cell Activation by TEC or BM-DC
 Untreated B6 primary renal TEC, TEC treated with different 
cytokines ( fig. 3 and  4 ), or LPS matured B6 BM-DC, were pulsed 
with 10 ng/ml of H-2K b -restricted OVA 257–264  peptide or the con-
trol peptide   -Gal 497–504  for 1 h at 37  °  C. After washing, APC were 
seeded into 96-well cell culture plates (2  ! 10 4 /well) with freshly 
isolated resting OT-1 CD8 T cells (2  ! 10 5 /well) in DMEM me-
dium supplemented with 5% FBS and co-incubated at 37  °  C to 
study OVA 257–264  peptide-specific OT-1 CD8 T cell activation. In 
some experiments, anti-mouse PD-L1 mAb (10   g/ml) was added 
to TEC 1 h prior to the addition of OT-1 CD8 T cells as indicated. 
The same concentration of isotype mAb was used as control.
After 24 h, supernatants from co-cultures were collected to ana-
lyze IFN-  content, using a mouse IFN-  -specific ELISA kit
(OptEIA TM  mouse IFN-  kit, BD Pharmingen).
 OT-1 CD8 T Cell Proliferation Assay
 To study OT-1 CD8 T cell proliferation induced by renal TEC 
and BM-DC, untreated B6 TEC, TEC treated with different cyto-
kines, or LPS matured B6 BM-DC were pulsed with 10 ng/ml of 
OVA 257–264  peptide or the control peptide   -Gal 497–504  for 1 h at 
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37  °  C. After washing, APC were seeded into 96-well plates (2  ! 
10 4 /well) with freshly isolated resting OT-1 CD8 T cells (2  ! 10 5 /
well) and incubated at 37  °  C. T cell proliferation was determined 
after 96 h by using a non-radioactive colorimetric CellTiter 96  
AQ ueous  One Solution Cell Proliferation Assay kit according to the 
manufacturer’s protocol (Promega). The proliferation index was 
calculated as:
 
 Proliferation Index =
 (OD experimental  – OD medium )/(OD T cells only  – OD medium )
 Determination of Antigen-Specific CD4 T Cell Proliferation 
and Cytokine Production Profile
 To study the MHC class II-restricted antigen presentation, B6 
renal primary TEC were first pretreated with IFN-  to enhance 
MHC class II surface upregulation for 48 h. BM-DC were har-
vested after LPS maturation. Cells were then collected and washed 
and seeded into 96-well culture plates (2  ! 10 4  APC/well) as de-
scribed above. The in vivo OVA-primed CD4 T cells (2  ! 10 5 /
well) were added to the APC in DMEM medium supplemented 
with 5% FBS and co-incubated at 37  °  C in the presence of OVA 
protein (50   g/ml). At time points 24, 48 and 96 h, supernatants 
were collected for measuring IL-2, IFN-  and IL-4 contents, using 
mouse specific ELISA kits (OptEIA TM  mouse ELISA kits, BD Bio-
sciences), according to the manufacturer’s protocols. Antigen-
specific CD4 T cell proliferation was determined after 96 h as 
describe above.
 Cytotoxicity by Activated OT-1 CD8 CTL to B6 TEC
 To measure antigen-specific cytolysis of renal TEC by CTL, 
activated OT-1 CD8 CTL were added to the cytokine-pretreated, 
OVA 257–264  peptide-loaded B6 TEC in 96-well U bottom culture 
plates at effector/target (E/T) ratios 10 to 1 (2  ! 10 5  CTL and 2  ! 
10 4  targets per well) in the presence or absence of anti-mouse PD-
L1 mAb (10   g/ml). After 4 h, 50   l of supernatants were col-
lected from each well for measuring the amount of lactate dehy-
drogenase (LDH) released upon cell lysis with the CytoTox 96  
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 Fig. 1. Constitutive surface expression of costimulatory molecules on BM-DC and on renal TEC. LPS matured 
murine BM-DC ( a ) or primary renal TEC ( b ) generated from B6 mice were stained with the indicated anti-
mouse costimulatory molecule mAbs for flow cytometric analysis. 
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 Statistics
 All experiments were performed in triplicates or quadrupli-
cates and were carried out at least 3 times. Data are expressed as 
mean  8 SD. Statistical analysis was performed using unpaired 
Student’s t test. Significance was accepted at p  ^  0.05.
 Results
 Costimulatory Molecule Expression Profile of Renal 
TEC and BM-DC
 We compared the constitutive surface expression of 
costimulatory molecules between renal TEC and den-
dritic cells by flow cytometric analysis. As shown in  fig-
ure 1 , unlike the LPS matured BM-DC generated from B6 
mice which expressed most costimulatory or coinhibi-
tory molecules tested on their surface ( fig. 1 a), B6 renal 
primary TEC did not constitutively express any tested 
molecules under non-inflammatory conditions ( fig. 1 b). 
Stimulation of B6 TEC with IFN-  (100 U/ml) for 48 h 
enhanced the expression of some costimulatory mole-
cules, including PD-L1, ICOS-L, CD40, as well as MHC 
class I and class II molecules ( fig. 2 ), whereas the surface 
upregulation of other molecules was not detected with 
flow cytometry after IFN-  treatment ( fig. 2 ).
 Since PD-L1 was the most prominent molecule upon 
IFN-  stimulation, we then examined whether pro- or 
anti-inflammatory cytokines other than IFN-  would 
also enhance the costimulatory molecule expression on 
TEC, especially PD-L1. For this purpose, B6 TEC were 
treated with IFN-  , IFN-  , IFN-  , TNF-  , IL-1, IL-2, IL-
4, IL-6, IL-10 or IL-12, alone or in combination, respec-
tively.  Figure 3 shows that surface PD-L1 was upregulated 
by stimulation of TEC with IFN-  and IFN-  , but not the 
other tested cytokines under our experimental conditions. 
Treated TEC with higher concentrations of IFN-  or IFN-
  did not further increase the surface expression of PD-L1 
as shown previously  [12] and had no effect on altering oth-
er costimulatory molecule expression on renal TEC (data 
not shown). The cytokine combinations of IFN-  /TNF-  , 
IFN-  /IFN-  , or TNF-  /IL-1/IL-6 did not show any syn-
ergetic effect on PD-L1 upregulation (data not shown). 
These results demonstrated that the  upregulation of co-
stimulatory molecules (e.g. PD-L1, ICOS-L and CD40) on 
cell surface was mostly limited to the interferons.
 Activation of OVA 257–264  Peptide-Specific OT-1 CD8
T Cells by Renal TEC or by BM-DC
 To examine the capacity of MHC class I and class II 
antigen presentation by renal TEC under inflammatory 
conditions, and to test whether the lack of costimulatory 
signals between renal TEC/T cells would influence the T 
cell activation, chicken OVA-specific CD4 and CD8 T cell 
activation was then investigated, using primary renal 
TEC or BM-DC as APC, respectively.
 To study the OVA 257–264  peptide-specific CD8 OT-1 T 
cell activation, B6 renal primary TEC pretreated with dif-



















Class I Class II
2nd Ab
IFN-γ (100 U/ml)
 Fig. 2. Costimulatory molecule expression on primary renal TEC 
stimulated with IFN-  . B6 primary TEC prestimulated with IFN-
  (100 U/ml) for 48 h were stained with the indicated anti-mouse 
costimulatory molecule mAbs for flow cytometric analysis. Filled 
gray histograms represent secondary antibody control stainings. 
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OVA 257–264  peptide and then co-incubated with resting 
OT-1 CD8 T cells. As shown in  figure 4 a, stimulation of 
OT-1 CD8 T cells by peptide-presenting renal TEC re-
sulted in much lower OT-1 CD8 T cell proliferation as 
compared to that obtained with BM-DC (pro liferation 
index 6.4 vs. 17). The T cell activation was antigen spe-
cific, since co-incubation of OT-1 CD8 T cells with   both  
 APC   that   were   pulsed   with   control   peptide   -Gal 497–504  
did not raise T cell proliferation nor IFN-  production 
( fig. 4 a, b). Similarly, a much lower amount of IFN-  was 
detected in the co-culture supernatants of renal TEC/
OT-1 CD8 T cells compared to those in the co-culture 
supernatants of BM-DC/OT-1 CD8 T cells ( fig. 4 b). In ad-
dition, blockade of surface PD-L1 on both IFN-  - and 
IFN-  -pretreated renal TEC significantly increased IFN-
  production by OT-1 CD8 T cells ( fig. 4 b). The PD-L1 
blockade effect was also observed on BM-DC surface 
( fig. 4 b). Together, these data demonstrate that renal TEC 
are poor antigen presenting cells for activating specific 
CD8 T cells and that PD-L1 molecule functions as a neg-
ative costimulatory molecule on both APC.
 To further examine whether high PD-L1 surface ex-
pression on renal TEC would directly influence CTL activ-
ity, the cytotoxicity of OT-1 CD8 CTL was tested by using 
high or low PD-L1-expressing renal TEC as targets ( fig. 3 ). 
OVA 257–264  peptide-dose titration experiments demon-
strated that loading IFN-  - or IFN-  -stimulated TEC 
with high antigen concentration cannot further increase 
the cytolyses of those TEC by OT-1 CTL , as compared to 
the TEC with low PD-L1-expression (untreated) ( fig. 5 ). 
Considering the fact that surface PD-L1 was upregulated 
only by IFN-  and IFN-  but not the other tested cyto-
kines, these results suggested that high PD-L1 surface ex-
pression protected renal TEC from the lysis by CTL.
 Stimulation of OVA Protein-Specific CD4 T Cells by 
Renal TEC or by BM-DC
 Next, we studied the capacity of presenting MHC class 
II antigens by renal TEC. OVA-specific CD4 T cell 
 proliferation was examined by using IFN-  -pretreated 
B6 TEC (to enhance MHC class II molecule expres - 
sion,  fig. 2 ) or LPS-matured BM-DC. Similarly to the 
OVA 257–264 -specific CD8 T cell proliferation, OVA-spe-
cific CD4 T cell proliferation induced by renal TEC was 
much lower than that induced by BM-DC (proliferation 
index 2.9 vs. 22.3,  fig. 6 a).
 The pattern and kinetics of cytokine production in the 
supernatants of APC/OVA-specific CD4 T cell co-cul-
tures were also determined ( fig. 6 b, c). Interestingly, renal 
TEC-stimulated CD4 T cells produced a high amount of 
IL-2, a low amount of IFN-  and a basal amount of IL-4 
( fig. 6 b and data not shown), indicating that renal TEC-
stimulated CD4 T cells did not further differentiate to the 
Th1 or Th2 subsets. In addition, the cytokine production 
by renal TEC-stimulated CD4 T cells started to decline 
after 48 h of stimulation, indicating that this activation 
was suboptimal and short-termed. On the contrary, BM-
DC-activated OVA-specific CD4 T cells secreted a low 
amount of IL-2, a high amount of IFN-  and a basal 
amount of IL-4 ( fig. 6 c and data not shown), showing a 
clear Th1 phenotype. Moreover, BM-DC-activated CD4 
cells continuously produced a high amount of IFN-  dur-
ing the whole experimental period ( fig. 6 c). Together 
these data indicate that CD4 T cells stimulated by BM-
DC were fully activated.
 To test the functional role of epithelial PD-L1 on CD4 
T cell activation, anti PD-L1 Abs were also used to block 
PD-L1 on APC surface at the beginning of the antigen 















 Fig. 3. PD-L1 expression on primary renal 
TEC treated with different cytokines. B6 
primary renal TEC pretreated with the in-
dicated cytokines were stained with anti-
mouse PD-L1 mAbs for flow cytometric 
analysis. 
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 Fig. 5. High PD-L1-expressing renal TEC 
were more resistant to the cytolysis by ac-
tivated OT-1 CD8 CTL. IFN-  - (250 U/ml) 
or IFN-  - (100 U/ml) pretreated, or un-
treated B6 TEC pulsed with different con-
centrations of OVA 257–264  peptide or con-
trol   -Gal 497–504  peptide were co-incubat-
ed with OT-1 CTL to determine their 
cytolyses as described in ‘Materials and 
Methods’. Data represent the mean % lysis 
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 Fig. 4. OVA 257–264  peptide-specific OT-1 
CD8 T cell activation by congeneic renal 
TEC or by BM-DC.  a Inflammatory cyto-
kine-pretreated (fig. 3) or untreated B6 
primary renal TEC- or LPS-matured BM-
DC pulsed with OVA 257–264  peptide were 
co-incubated with resting OT-1 CD8 T 
cells for 96 h for determining the T cell 
proliferation as described in ‘Materials 
and Methods’. Data represent the mean 
proliferation index  8 SD.  b Untreated, 
IFN-  - (250 U/ml) or IFN-  - (100 U/ml) 
pretreated and OVA 257–264  peptide- or con-
trol peptide-pulsed renal B6 TEC or BM-
DC were co-incubated with resting OT-1 
CD8 T cells as described in ( a ), respective-
ly, in the presence or absence of the PD-L1-
blocking mAbs (final concentration 10 
  g/ml). After 24 h, supernatants were col-
lected to determine the IFN-  production 
by IFN-  ELISA. Data represent the mean 
amount of IFN-   8 SD.  * p  ^  0.05 when 
compared with TEC without Ab block-
ade. 
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ade did not significantly change T cell proliferative re-
sponses induced either by renal TEC or by BM-DC 
( fig. 6 a), whereas blockade of PD-L1 on TEC surface sig-
nificantly elevated IL-2 (2-fold) and IFN-  (2.5-fold) pro-
ductions in the supernatants of renal TEC/CD4 T cell co-
cultures measured after 24 or 48 h, respectively ( fig. 6 b). 
The significant increase of IFN-  production in BM-DC 
activated CD4 T cells was also observed after 24 and
48 h (1.5-fold;  fig. 6 c). The non-effectiveness of PD-L1 Ab 
blockade in T cell proliferation assays may be due to the 
dissociation of the Ab/PD-L1 binding or the degradation 
of the antibodies during 96 h incubation, since the differ-
ence between cytokine production in the cell co-cultures 
with or without Ab blockade also started to diminish af-
ter 48 h ( fig. 6 b, c).
 Discussion
 In this study, we investigated the profile of costimula-
tory molecules expressed on renal TEC upon stimulation 
with various inflammatory cytokines. Compared to den-
dritic cells, renal TEC were poor antigen-presenting cells 



















































































































 Fig. 6. Comparison of OVA protein-spe-
cific CD4 T cell responses induced by au-
tologous renal TEC or by BM-DC.  a IFN-
  -pretreated, untreated B6 TEC or BM-
DC were loaded with OVA protein and 
incubated with in vitro primed CD4 T 
cells for 96 h to determine the specific T 
cell proliferation as described in ‘Materials 
and Methods’.  b The supernatants of CD4 
T cell/APC co-cultures described in ( a ) 
were collected at time points 24, 48 and 96 
h, respectively, to determine the cytokine 
production profile with specific IL-2 or 
IFN-  ELISA. While indicated, anti-PD-
L1 Abs were included in the experiments. 
Data represent the mean amount of cyto-
kine  8 SD.  * p  ^  0.05,  ** p  ^  0.001, when 
compared with anti PD-L1 Ab blockade. 
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study, Singer et al. [16] reported that presentation of an-
tigens by renal TEC to a CD4 T cell clone resulted in func-
tional inactivation of the T cells. Frasca et al. [17] com-
pared the antigen presentation capacity between human 
primary TEC and EBV transfected B cells for activating 
CD4 T cells and demonstrated that IFN-  -treated human 
primary TEC induced allospecific tolerance. However, 
the molecular mechanisms involved in the T cell activa-
tion by renal TEC are still not fully understood.
 The expression profile of MHC and costimulatory 
molecules on professional or non-professional APC (e.g. 
renal TEC) can greatly influence the magnitude of T cell 
activation. BM-DC constitutively expresses a higher 
quantity of MHC molecules than renal TEC under non-
inflammatory conditions. However, the handicapped T 
cell activation induced by renal TEC cannot be simply 
explained by the MHC molecule expression, since stimu-
lation of renal TEC with pro-inflammatory cytokines is 
known to effectively upregulate MHC class I and II mol-
ecules on TEC, whereas their ability of activating T cells 
is not significantly improved. We demonstrated in this 
study that TEC expressed a low level of surface costimu-
latory molecules under noninflammatory conditions and 
that only a few costimulatory molecules were upregulated 
upon stimulation with IFNs. Alternatively, other path-
ways might also be involved in T cell response and func-
tion under inflammatory conditions. Lang et al. reported 
that, in addition to the upregulation of MHC molecules 
by LCMV infection, Toll-like receptor (TLR) engagement 
converted T cell autoreactivity into overt autoimmune 
disease in a mouse model  [18] . Nevertheless, the lack of 
costimulatory signals on renal TEC might be at least 
partly responsible for the impaired T cell activation.
 The classical costimulatory molecules B7.1 and B7.2 
are not expressed by renal TEC, neither at the mRNA 
level nor at the cell surface  [10, 19, 20] . Thus, both B7/
CD28 costimulatory and B7/CTLA-4 co-inhibitory path-
ways cannot play a major role in renal TEC and T cell 
interaction. Although mRNA transcripts for B7-H3, B7-
H4, OX40-L and 4-1BBL were detected in murine pri-
mary renal TEC (data not shown), they were not expressed 
on the surface of renal TEC, even after stimulation with 
inflammatory cytokines. PD-L1 was the most promi-
nently expressed costimulatory molecule among the IFN-
upregulated molecules. Therefore, PD-L1 may provide an 
alternative negative signaling to control inflammatory 
responses in the absence of B7/CTLA-4 interaction.
 PD-L1 is widely involved in immunoregulatory pro-
cesses, e.g. tumor escape mechanisms, inflammatory re-
sponses, organ-specific autoimmunity, transplantation 
 [4, 21–24] . Thompson et al. [25] recently reported that the 
upregulation of PD-L1 was associated with a higher mor-
tality in renal cell carcinoma (RCC) patients, suggesting 
that PD-L1 expressed on tumor cells could directly in-
hibit functions of infiltrating tumor-specific T cells. Mice 
which are deficient in PD-L1 and/or PD-1 have a strong 
tendency to develop autoimmune diseases  [26, 27] . Up-
regulation of PD-L1 was observed in the rejected al-
lografts of kidney, heart, skin and islets of pancreas  [8, 
28–30] , suggesting that PD-L1 plays an important role in 
the regulation of the rejection process.
 We and others previously described that PD-L1 is 
strongly upregulated by TEC in the rejected murine kid-
ney transplants as well as in inflamed human kidneys  [8, 
10, 11] . Recently, we demonstrated that renal TEC with 
high surface PD-L1 induced by IFNs were more resistant 
to the cytolysis by OT-1 CTL. This lower cytolysis of TEC 
can be overcome by PD-L1 blockade  [12] . In the present 
study, the blockade of PD-L1 on renal TEC not only in-
creased CD8 T cell activation, but also OVA-specific 
CD4 T cell proliferation and cytokine production. De 
Haij et al. [10] observed that human TEC downregulated 
the CD3/CD28-activated T cell proliferation and modu-
lated the cytokine production profile of T cells. Taken 
together, we speculate that renal TEC may use PD-L1 to 
suppress the activity of infiltrating T cells during in-
flammation, hence, to protect renal tissue from the dam-
age induced by immunopathologic responses. Further in 
vivo studies are required to explore the protective role of 
PD-L1 in parenchymal immune responses in the kid-
ney.
 Taken together, our data demonstrated that the lack of 
costimulatory signals between renal TEC and T cells 
greatly impaired the antigen-specific T cell activation. 
The limited costimulatory molecule expression on renal 
TEC may be essential to keep the local immune health in 
the renal tissues. The IFN-induced PD-L1 upregulation 
on renal TEC may be crucial to retain the integrity of the 
kidney under immunopathologic conditions and, there-
fore, may play an important role in renal parenchymal 
immunoregulation.
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Abstract
Background. Activated infiltrating T cells play a crucial
role in nephritic inflammation via the direct interaction
with proximal tubular epithelial cells (TEC). Under
inflammatory conditions, major histocompatibility
complex class I and II molecules are upregulated on
the surface of renal TEC, enabling them to function as
‘non-professional’ antigen-presenting cells (APC) to
activate T cells, and, in turn to be targeted by cytotoxic
T lymphocytes (CTL) to cause tissue damage. It is
known that co-stimulatory (e.g. B7/CD28) and
co-inhibitory (e.g. PD-L1/PD-1) signals regulate and
determine the magnitude of T cell responses. In this
study, we examined the expression of co-stimulatory
molecule PD-L1 by renal TEC and the functional role
of renal PD-L1/PD-1 pathway in regulating CD8þ T
cell responses induced by antigen-presenting renal
TEC.
Methods. Renal TEC were treated with type I and
type II interferons (IFN-a, IFN-b or IFN-g). PD-L1
expression was then determined with flow cytometry
and RT-PCR. To investigate the functional
role of renal epithelial PD-L1 on CD8þ CTL
responses, H-2Kb-restricted, OVA257–264 peptide-
specific CD8þ T cells isolated from OT-1T cell
receptor transgenic mice were co-incubated with
IFN-stimulated, OVA257–264 peptide-pulsed congeneic
TEC. The activation of OT-1 CD8þ CTL was
estimated either by IFN-g production in the super-
natants of co-cultures or by CTL activity.
Results. TECs do not constitutively express PD-L1 on
their surface. However, a strong and dose-dependent
upregulation of PD-L1 was observed on TEC after
stimulation with IFN-b or IFN-g, but not with IFN-a.
OVA257–264 peptide pulsed-TEC were able to activate
OT-1 CD8þ T cells, indicated by the high amount of
IFN-g production and cytolysis of TEC. Blockade of
epithelial PD-L1 with specific mAb significantly
increased OT-1 CD8þ T cell activity, indicating that
the PD-L1 pathway has a negative effect on CD8þ T
cell responses. Moreover, IFN- b- or IFN-g-stimulated
TEC with high surface PD-L1 expression were more
resistant to the cytolysis by OT-1 CTL.
Conclusion. Together our data reveal that the renal
PD-L1/PD-1 pathway has a negative effect on CD8þ
CTL activation. PD-L1 might, therefore, act as a
protective molecule on TEC, downregulating the
cytotoxic renal parenchymal immune response.
Keywords: CD8þ T cells; interferon; PD-L1; renal
tubular epithelial cells
Introduction
The proximal renal tubular epithelium is an important
target in tubulointerstitial immune-mediated kidney
diseases [1]. Activated infiltrating T cells play a crucial
role in nephritic inflammation via the direct interaction
with renal proximal tubular epithelial cells (TEC).
Thus, infiltrating CD4þ and CD8þ T cells surrounding
the tubular epithelium are found in abundance in most
tubulointerstitial disease processes, including tubuloin-
terstitial nephritis and renal allograft rejection [2,3].
The ability of renal TEC to promote T cell activation is
attributable to their expression of major histocompat-
ibility complex (MHC) class I and class II molecules
and co-stimulatory molecules. Renal TECs act as
non-professional antigen-presenting cells (APC) to
trigger specific T cell responses, and can in turn be
targeted by antigen-specific cytotoxic T cells (CTL)
during immune-mediated kidney diseases. Although it
is well known that CD8þ T cells are the predominant
effector cells in tubulointerstitial renal injury and
allogeneic kidney transplantation, the regulatory
mechanisms of CD8þ T cell responses to TEC
have not been fully elucidated yet [4–8]. In particular,
studies examining the role played by B7-related
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co-stimulatory molecules on CD8þ T cell responses to
TEC are lacking.
Co-stimulatory pathways effectively regulate T cell
activation and tolerance [9,10]. The classical
co-stimulatory molecules expressed on professional
APC include B7.1, B7.2 and CD40. Interactions of
B7/CD28 and CD40/CD40L provide positive
signals to upregulate T cell responses, whereas the
B7/CTLA-4 pathway leads to suppression of T cell
responses. Recently, several novel co-stimulatory
and co-inhibitory molecules have been discovered.
A negative T cell regulatory pathway which could
potentially be important for immune-mediated tubu-
lointerstitial injury is represented by the interaction
between programmed death-1 (PD-1) expressed on
activated T cells, and its two ligands PD-L1 and PD-L2
which are expressed on APC [9–11]. Recently, we and
others have described that PD-L1 is strongly upregu-
lated by TEC in rejected kidney transplants as well as
in inflamed kidneys [2,3,12], suggesting that it may
play an important regulatory role in immune-mediated
renal injury.
We and others have previously shown that IFN-g
treatment rapidly and strongly upregulated PD-L1 but
not PD-L2 on cultured murine TEC, and that blockade
with mAbs of PD-L1 on TEC significantly increased
antigen-specific CD4þ T cell responses [2]. Thus far the
functional role of the renal epithelial PD-L1/PD-1
pathway in CD8þ CTL responses has not been
investigated. In this study we first examined in detail
the differential effect of type I and type II interferons
(IFNs) on PD-L1 and MHC class I expression in
renal TEC, then examined the functional role of the
PD-L1/PD-1 pathway on the antigen-specific activa-
tion of CD8þ T cells by TEC, and the cytolytic effect to
TEC by activated CD8þ CTL.
Materials and methods
General reagents
Cell culture reagents were obtained from Invitrogen
(Gaithersburg, MD) and Sigma (St. Louis, MO). Recombi-
nant mouse IFN-a, IFN-b and IFN-g were purchased from
R&D Systems (Oxford, UK). Anti-mouse PD-L1, PD-1 and
MHC class I monoclonal antibodies (mAbs) were purchased
from eBioscience (San Diego, CA). Biotin-conjugated anti-
mouse H-2Kk was obtained from BD Biosciences (San Jose,
CA). Chicken ovalbumin peptide 257-264 (OVA257–264,
amino acid sequence SIINFEKL) was purchased from
Proimmune (London, UK). A control H-2Kb restricted
b-galactosidase peptide 497–504 (b-Gal497–504, amino acid
sequence ICPMYARV) was a kind gift from Prof. Groettrup
of Constance University, Germany. Anti-mouse CD8a (Ly-2)
MACS microbeads were obtained from Miltenyi Biotec
(Bergisch Gladbach, Germany).
Animals, cell lines and renal proximal TEC cultures
T cell receptor (TCR) transgenic OT-1 mice [13] were
obtained from Jackson Laboratories (Bar Harbor, ME).
C57BL/6 (B6) and C3H/HeN (C3H) mice were purchased
from Harlan (Horst, Netherlands). All animals were used at
8–16 weeks of age. The study protocol was approved by the
regulatory commission for animal studies of the Canton
Zurich, Switzerland. Primary cultures of murine renal
proximal TEC were prepared as described previously [14].
Primary renal TEC and SV40-transformed murine renal
proximal TEC line C1.1 were cultured on collagen-coated cell
culture plates in modified K1 medium as previously
described [14]. A murine macrophage cell line RAW 264.7
and EL-4 cells were grown in complete Dulbecco’s modified
Eagle’s medium (DMEM) with Glutamax, supplemented
with 1000U/ml penicillin, 100mg/ml streptomycin and
10% FBS. All cells were maintained at 378C with 5% CO2.
RNA extraction and RT-PCR analysis
Total RNA from cell cultures was extracted using the
RNeasy mini kit (Qiagen, Valencia, CA). All samples
were quantified by the measurement of the optical density
at 260 nm, and equal amounts were amplified by reverse
transcription-polymerase chain reaction (RT-PCR) (Qiagen
OneStep PCR kit, Qiagen). Primer sequences of PD-L1
were determined as previously described [2]. To ensure
even amounts of template, the rat housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
co-amplified as described previously [15]. Reaction mixtures
were separated on 1.5% agarose gels containing ethidium
bromide, and bands were detected under UV light
and analysed with the Bio-Image System ChemidocTM
XRS (Bio-Rad, Hercules, CA).
Flow cytometric analysis
RAW264.7, the renal TEC line C1.1 and primary cultures of
renal TEC were stimulated with IFN-a, IFN-b or IFN-g
for 48 h. Cells were harvested by light trypsinization, washed
twice with Hanks’ Balanced Salt Solution (HBSS, Invitrogen)
and suspended in PBS containing 2% FBS and 0.1% sodium
azide. Before staining with the primary antibody, macro-
phages were pre-incubated with anti-mouse CD16/CD32 Ab
for 15min to block FcR binding. After incubating with
primary mAbs for 45min on ice, cells were washed twice and
incubated with the appropriate FITC-conjugated secondary
Ab for 30min. Cells were then washed and analysed using an
FACScan flow cytometer and the Cell QuestTM software
(Becton Dickinson).
Isolation of CD8þ T cells from OT-1 mice
Spleen and lymph nodes (LN) were harvested from 8–16-
week-old naı¨ve OT-1 mice. CD8þ cells were isolated using
anti-mouse CD8a (Ly-2) MACS microbeads according to the
manufacturer’s protocol. The freshly isolated OT-1 CD8þ T
cells were either used immediately for antigen presentation
assays, or were activated in vitro. To activate OT-1 CTL,
OT-1 CD8þ T cells were stimulated with B6 splenocytes
pulsed with 0.1 mg/ml of OVA257–264 peptide and were
incubated in DMEM medium supplemented with 5 mM
2-mercaptomethanol, 1% HEPES, 1000U/ml penicillin,
100mg/ml streptomycin and 10% FBS at a T cell to APC
ratio of 1:5. After 6 days of stimulation, activated OT-1 CTL
were used for CTL assays.
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Antigen presentation of renal B6 TEC to
resting OT-1 CD8þ T cells
To study the antigen presentation of the H-2Kb-restricted
peptide OVA257–264 by congeneic primary TEC to OT-1
CD8þ T cells, B6 primary TEC were pre-treated with IFNs
for 48 h. Cells were washed to remove excess cytokines and
were harvested by light trypsinization. The cells were then
pulsed with 0.1 mg/ml of OVA257–264 peptide or the control
H-2Kb-restricted b-Gal497–504 peptide for 1 h at 378C. After
washing, TEC were counted and seeded in 96-well U-bottom
cell culture plates (Costar) in DMEM medium supplemented
with 5% FBS, 1000U/ml of penicillin and 100mg/ml of
streptomycin. The resting OT-1 CD8þ T cells were added to
TEC cultures and were co-incubated at 378C. Anti-mouse
PD-L1 mAb (10 mg/ml) were added to TEC 1h prior to the
addition of OT-1 CD8þ T cells as indicated. After 24 h,
supernatants from co-cultures were collected and analysed
for IFN-g content using a mouse IFN-g-specific ELISA kit
(OptEIATM mouse IFN-g kit, BD Pharmingen). In control
experiments, OVA257–264 or b-Gal497–504 peptide-pulsed EL-4
cells were used.
IFN-g enzyme-linked immunosorbent spot (ELISPOT)
assays (Diaclone, Besanc¸on, France) were also used to
determine the IFN-g production induced by resting OT-1
CD8þ T cells after activation by OVA257–264-presenting
congeneic TEC. Briefly, untreated B6 TEC or EL-4 cells were
pulsed with 0.1 mg/ml of OVA257–264 or b-Gal497–504 peptide
for 1 h at 378C. The cells were then washed and seeded into
the ELISPOT plate. Resting OT-1 CD8þ T cells were added
to the TEC cultures and were co-incubated for 18 h at 378C.
ELISPOT plates were developed according to the manufac-
turer’s protocol.
Cytotoxicity by activated OT-1 CD8þ CTL to B6 TEC
To measure antigen-specific cytolysis of renal TEC
by CTL, activated OT-1 CD8þ CTL were added to
IFN-pre-treated, OVA257–264 peptide-loaded B6 TEC
in 96-U bottom cell culture plates at various effector/target
(E/T) ratios, in the presence or absence of anti-mouse
PD-L1 mAb (10 mg/ml). After 4 h of incubation, 50 ml of
supernatants were collected from each well for measuring
the amount of lactate dehydrogenase (LDH) released upon
cell lysis by using the CytoTox 96 non-radioactive
cytotoxicity assay kit (Promega) according to the
manufacturer’s protocol. The percentage of target lysis was
calculated as follows:
% lysis ¼100 ðexperimental LDH release spontaneous
LDH release of targets spontaneous LDH
release from T cellsÞ=ðmaximum LDH release
 spontaneous LDH release of targetsÞ:
Statistics
Results from IFN-g ELISA, ELISPOT or CTL assays are
expressed as means SD of triplicate or quadruplicate
determinations from the representative experiments that
gave rise to similar results. Statistical analysis was performed
using unpaired Student’s t-test. Significance was accepted at
P 0.05.
Results
Stimulation of renal proximal TEC with IFN- and
IFN- upregulated PD-L1
Murine macrophage RAW246.7 cells and murine
primary proximal TEC cultures prepared from
C57BL/6J (B6 TEC) mice were stimulated with
200U/ml of IFN-b or 100U/ml of IFN-g for 1–4 h
for determining changes in mRNA expression of
PD-L1. As shown in Figure 1, PD-L1 mRNA
was constitutively detected in macrophages and renal
TEC. A strong increase of steady-state PD-L1 mRNA
levels was observed in macrophages after 1 and 4 h of
stimulation with either IFN-b or IFN-g (Figure 1A),
in renal B6 TEC after 1 and 4 h of stimulation with
IFN-b, and slightly delayed after 4 h with IFN-g
(Figure 1B). Stimulation of TEC with IFN-a even
at a higher concentration (up to 1000U/ml) did
not increase PD-L1 mRNA expression in TEC (data
not shown).
The surface expression of PD-L1 and MHC class I
on TEC was examined after stimulation with IFN-b or
IFN-g for 48 h. Expression of PD-L1 on untreated
C1.1 or primary C3H renal TEC cultures (the original
of C1.1 cells) was negligible, contrasting with RAW
264.7 macrophages which constitutively express sur-
face PD-L1 (Figure 2A). Stimulation with IFN-b or
IFN-g strongly upregulated PD-L1 (Figure 2A) and
MHC class I molecules (Figure 2B) on all cells tested.
The upregulation of both PD-L1 and MHC class I
molecules on IFN-b or IFN-g-stimulated renal TEC
was dose-dependent (our previous results [2] and
Figure 3). Although stimulation of TEC with IFN-a
did not increase PD-L1 surface expression even when a
high dose (1000U/ml) was used, a dose-dependent,
strong increase of MHC class I expression was
observed (Figure 3B), suggesting that IFN-a












Time 1h 1h 4h 4h 1h 4h0h
Fig. 1. RT-PCR analysis of PD-L1 mRNA expression in renal TEC
treated with IFNs. Murine macrophage RAW264.7 cells (positive
control cell line) (A) and primary renal TEC cultures generated
from B6 mice (B) were treated with IFN-b (200U/ml) or IFN-g
(100U/ml) for 1 or 4 h. Results are representative of two independent
experiments which gave similar results.
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antigen-presenting cells. Similar results were also
obtained by IFN-stimulation of primary TEC that
were generated from different mouse strains, including
C57BL/6, C3H, BALB/c and AKR/J (data not
shown), indicating that this phenomenon is not limited
to a specific cell line or mouse strain.
Activation of resting OT-1 CD8þ T cells by TEC
We used CD8þ T cells isolated from OT-1 TCR
transgenic mice to examine the ability of renal TEC to
present MHC class I-restricted antigenic peptide. OT-1
mice contain transgenic TCR genes in CD8þ T cells,
which are designed to recognize the chicken ovalbumin
protein residues 257–264 in the context of H-2Kb
(OVA257–264) [13]. FACS analysis showed that resting
OT-1 CD8þ T cells express PD-L1 but not PD-1,
whereas both molecules were strongly upregulated on
in vitro-activated OT-1 CTL (Figure 4).
Antigen titration experiments were then performed
to examine the capacity of presenting OVA257–264
peptide to the resting OT-1 CD8þ T cells by renal B6
TEC. Similar amounts of IFN-g were detected from
supernatants of OT-1 CD8þ T cell cultures sensitized
either by OVA257–264 pulsed congeneic TEC (from
C57BL/6 mice) or by EL-4 cells (Figure 5A). These
results were further confirmed by IFN-g ELISPOT
assays. As shown in Figure 5B and C, resting OT-1
CD8þ T cells activated by either OVA peptide-
presenting B6 TEC or EL-4 cells gave rise to a
comparable level of IFN-g production when captured
and visualized by IFN-g ELISPOTs. These results
demonstrate that renal TEC have a strong capacity of
presenting MHC class I-restricted antigenic peptides to
activate antigen-specific CD8þ T cells in vitro.
PD-L1 on renal TEC inhibited antigen presentation
to OT-1 CD8þ T cells
We studied next whether PD-L1 was able to regulate
CD8þ T cell responses. For this purpose, TEC were
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Fig. 2. PD-L1 and MHC class I expression on renal TEC stimulated with IFN-b (200U/ml) or IFN-g (100U/ml) for 48 h. Murine
macrophage line RAW264.7, renal TEC line C1.1 and primary TEC cultures generated from C3H mice (18 TEC) were stained with anti-
mouse PD-L1 (A) or MHC class I (B) mAbs for flow cytometric analysis. Results are representative of four independent experiments.
1530 Y. Waeckerle-Men et al.
33
upregulate PD-L1. Cells were then collected, washed
and loaded with OVA257–264 peptide. Anti-PD-L1 mAb
was added to block PD-L1 on TEC before activating
the resting OT-1 CD8þ T cells. Blockade of PD-L1
significantly increased OT-1 CD8þ T cell activation, as
revealed by higher amounts of IFN-g, compared to
those with TEC without PD-L1 blockade (Figure 6).
The reaction was antigen-specific and MHC class
I-restricted, since irrelevant b-Gal497–504 peptide-pulsed
TEC failed to induce OT-1T cell activation and C1.1
cells (H-2Kk) pulsed with OVA257–264 peptide did not
induce IFN-g production by OT-1T cells (data not
shown). These results indicated that PD-L1-expressing
renal epithelial cells modulated the antigen-specific
CD8þ T cell activation.
PD-L1 partially protected TEC from cytolysis
by OT-1 CTL
We then examined whether OVA-presenting TEC
would be the direct targets of OT-1 CD8þ CTL, and
whether epithelial PD-L1 plays a functional role on
CTL responses. For this purpose, OVA257–264 peptide-
pulsed B6 renal TEC, pretreated with IFN-a, IFN-b
and IFN-g or untreated, were used as target cells to
study the cytotoxicity of OT-1 CD8þ T cells. Resting
OT-1 CD8þ T cells isolated from naı¨ve OT-1
mice failed to kill OVA257–264 peptide-presenting
target cells, including renal B6 TEC or EL-4 cells
(data not shown). In contrast, in vitro-stimulated/
activated OT-1 CD8þ T cells demonstrated a strong
cytotoxicity when OVA257–264 peptide-presenting B6
TEC or EL-4 cells were used as targets (Figure 7A).
Only basal cytolysis of target cells was observed when
TEC and EL-4 cells were pulsed with the irrelevant
H-2Kb peptide b-Gal497–504 (Figure 7A). Importantly,
when IFN-b and IFN-g-stimulated TEC were used as
targets in the same CTL assay, significantly lower
cytolysis was observed compared with untreated TEC.
The lysis of TEC treated with IFN-a did not show
significant difference when compared with untreated
TEC (Figure 7A). Considering that IFN-b or IFN-g
treatment upregulated high-surface PD-L1 molecule
expression, this may be indirect evidence that the
surface PD-L1 protects TEC from the cytolysis by
CTL. To further clarify this point, anti-PD-L1 anti-
bodies were added to block the surface PD-L1 during
CTL assay. As shown in Figure 7B, the PD-L1 Ab
blockade led to a significant increase of cytolysis of
TEC treated with IFN-b or IFN-g, respectively, while
adding anti-PD-L1 mAb to untreated or IFN-a-treated
TEC did not alter the cytolytic effect of OT-1 CD8þ T
cells. Taken together, these results demonstrate that
PD-L1 expressed on renal TEC plays an inhibitory role
on CTL responses, reducing T cell activation and





100 101 102 103
100 101 102 103
IFN-β
IFN-α
100 101 102 103 104



































Fig. 3. PD-L1 and MHC class I expression on renal TEC stimulated
with type I IFNs. C1.1 cells were stimulated with the indicated
concentrations of IFN-a or IFN-b for 48 h, and were stained with
anti-mouse PD-L1 (A) or MHC class I (B) mAbs for flow cytometric
analysis. Results are representative of two independent experiments.
Resting
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Fig. 4. Flow cytometric analysis of PD-1 and PD-L1 expression on
OT-1 CD8þ T cells. Resting or OVA257–264 peptide-stimulated OT-1
CD8þ T cells were stained with anti-mouse PD-1 or PD-L1 mAbs for
flow cytometric analysis. Results are representative of two indepen-
dent experiments.
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Discussion
In this study we demonstrate that the expression of
PD-L1 on TEC is strongly and rapidly upregulated by
IFN-b and IFN-g, but not by IFN-a. Furthermore, we
show that the PD-L1/PD-1 pathway inhibits antigen-
specific CD8þ T cell activation by renal TEC. In
addition, the blockade of PD-L1 on TEC leads to
an enhanced cytolytic activity of CTL in an MHC class
I-restricted manner. PD-L1 on renal TEC, therefore,
provides a negative signal for antigen-specific CD8þ T
cell responses.
CD8þ T cells are major contributors in cell-mediated
immune responses in tubulointerstitial renal diseases
and are responsible for the tubular destruction [4,16].
However, the mechanisms that regulate the intrarenal
CD8þ T cell activity have not been investigated in
detail. Apart from MHC class I complex/TCR inter-
actions that are crucial for initiating T cell activation,
a variety of co-stimulatory and co-inhibitory pathways
are known to influence the cytolytic potential of
CD8þ T cells [9,10,17]. Among those co-stimulatory
pathways, B7/CD28 provides the most prominent
activation signal for CD8þ T cells. However, as B7.1
and B7.2 are hardly expressed by renal TEC, the
relevant co-stimulatory pathways might be different
for TEC-driven CD8þ T cell responses. Similarly, the
co-inhibitory B7/CTLA-4 interaction might also not
operate on TEC for the same lack of expression
of B7 molecules. Considering that only limited
co-stimulatory or co-inhibitory molecules such as
PD-L1, ICOS-L and CD40 are expressed in renal
TEC (our unpublished data), thus PD-L1 may be one
of the major co-inhibitory molecules regulating
renal epithelial CD8þ CTL responses. Our current
findings that the epithelial PD-L1/PD-1 pathway
has an immunological regulatory function on CD8þ
CTL responses are also consistent with other studies,
including cancer immunity, pathogen-induced CD8þ T
cell responses, autoimmune diseases and organ
transplantation [9,10,18].
PD-L1 is aberrantly expressed by various
human carcinomas [18–23]. The expression of














































































Fig. 5. OVA-presenting renal TEC activate resting OT-1 CD8þ T cells to produce high amounts of IFN-g. (A) Antigen titration assay.
Untreated primary B6 TEC or EL-4 cells (1 104 per well) pulsed with increasing concentrations of OVA257–264 peptide were co-incubated
with resting OT-1 CD8þ T cells (5 104 per well). After 24 h, OT-1 CD8þ T cell activation was determined with IFN-g ELISA. Results
represent the mean amount of IFN-g SD. (B and C) IFN-g ELISPOT assay. Untreated B6 TEC or EL-4 cells (1 104 per well) were pulsed
with 100 ng/ml of OVA257–264 or b-Gal497–504 peptide, then were co-incubated with resting OT-1 CD8
þ T cells (5 104 per well) in pre-coated
murine IFN-g ELISPOT plates. After 18 h, plates were developed, and spots were counted as described in ‘Materials and methods’. Wells
containing only TEC or OT-1 CD8þ T cells were included as controls. Data represent the mean spots per well SD. Representative individual
ELISPOT wells with different experimental setting are shown in C.
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T cell functions, resulting in defective host anti-tumour
immunity. For example, high PD-L1 expression in
human renal cell carcinomas is correlated with tumour
invasiveness and markedly increased the risk of death
from cancer [19]. In an animal study, resistance of PD-
L1-positive tumour cells to the cytolysis by tumour-
specific CTL has been observed, and this could
be abrogated by the treatment with anti-PD-L1 or
anti-PD-1 antibodies [24].
Interesting results have been obtained regarding the
role of PD-L1 in chronic infections. Barber et al. [25]
demonstrated that the in vivo blockade of either PD-L1
or its receptor PD-1 with antibodies enhanced lym-
phocytic choriomeningitis virus (LCMV)-specific
CD8þ T cell responses, and restored the function
of those ‘exhausted’ CD8þ T cells during chronic
LCMV infection. It is tempting to speculate that the
IFN-stimulated expression of PD-L1 on TEC could
protect intratubular viruses such as Epstein–Barr or
the BK polyoma virus, promoting, therefore, their
cytopathic effects [26,27].
PD-L1 is also an important control molecule
in autoimmunity and transplant rejection. Mice that
are deficient in PD-L1 and/or PD-1 have a strong
tendency to develop autoimmune diseases [28,29].
In disease models such as autoimmune diabetes
and experimental autoimmune encephalomyelitis
(EAE), upregulated PD-L1 expression has been
observed [30–33]. Enhanced expression of PD-L1 has
also been reported in allograft transplants of kidney,
heart, skin and islets of pancreas, indicating that
PD-L1 plays a role in the downregulation of the
rejection process [2,34–36]. Finally, PD-L1 is involved
in feto-maternal tolerance mechanisms [37]. Together,
these data suggest that the PD-L1/PD-1 pathway plays
an important role in peripheral and parenchymal
immune tolerance.
During inflammation, the tubulointerstitium and/or
TEC are exposed to many pro-inflammatory cytokines
that are produced by infiltrating immune cells. We
have previously reported that IFN-g treatment led to
the strong increase of PD-L1 expression in TEC [2]. An
additional important finding in this study is that the
type I interferon IFN-b is able to induce strong PD-L1
expression in TEC and that the IFN-b-induced PD-L1
on TEC reduced specific CD8þ CTL responses. IFN-b
is the principal immune modulation agent to treat
patients with multiple sclerosis (MS) [38–40].
Schwarting et al. [41] reported that IFN-b treatment
prolonged survival of MRL-Faslpr mice with experi-
mental systemic lupus erythematosus (SLE) and
reduced kidney pathology. The molecular mechanisms
of IFN-b treatment on autoimmune diseases still
remain unclear, but one hypothesis might be that the
administration of IFN-b is able to induce an upregula-
tion of PD-L1 on peripheral professional APC and on
non-lymphoid tissues, thereby downregulating T cell
proliferation and the infiltration of leukocytes. Indeed,
Schreiner et al. [40] showed that the therapeutic
application of IFN-b leads to a significant increase of
PD-L1 level in MS patients, suggesting that PD-L1
might be responsible, at least in part, for the protective
effect in this therapy. More detailed studies are
required to test this hypothesis
IFN-g is a pivotal pro-inflammatory cytokine in
immune-mediated renal diseases [42]. However, its
immunoregulatory effect in vivo is still unclear so far.
Some studies showed that IFN-g is essential for the
disease development [43,44]; whereas others reported
that endogenous IFN-g plays a protective role in renal
organ-specific autoimmunity [45]. Although IFN-g
treatment showed immunoregulatory effect to down-
regulate specific CTL responses under our in vitro
experimental conditions, its in vivo role of organ-
specific immunomodulation still needs to be
elucidated.
The results obtained from the current study
were based on an in vitro experimental system
that used primary TEC cultures and antigen-specific
CD8þ CTL from OT-1 transgenic mice to study the
co-stimulatory function of epithelial PD-L1.
The in vivo role of intrarenal PD-L1 on modulating
A
























































































Fig. 6. Blockade of PD-L1 on renal TEC increased OVA
peptide-specific OT-1 CD8þ T cell activation. IFN-b (A) or
IFN-g (B) stimulated, OVA257–264 or b-Gal497–504 peptide-pulsed
(100 ng/ml) renal B6 TEC (2 104 per well) were co-incubated with
resting OT-1 CD8þ T cells (1 105 per well) in the presence or
absence of the PD-L1 blocking mAbs (final concentration 10 mg/ml)
for 24 h. OT-1 CD8þ T cell activation was determined by IFN-g
production from the collected supernatants with IFN-g ELISA.
Data represent the mean amount of IFN-g SD. One out of the four
independent experiments is shown. *P 0.05; **P 0.001, when
compared with TEC without Ab blockade (Student’s t-test).
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T cell responses requires further verification.
Nevertheless, considering the evidence that the in vivo
PD-L1 expression is markedly enhanced in kidneys
with tubulitis in renal allograft rejection [2] and in
lupus nephritis [46], and our previous findings that the
renal epithelial PD-1/PD-L1 pathway inhibits antigen-
specific CD4þ T helper cell activation in vitro [2], our
data indicated that the renal epithelial PD-L1/PD-1
pathway may inhibit both CD4þ and CD8þ T cell
responses and protect the renal epithelial cells from the
attack of CTL.
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Fig. 7. High PD-L1-expressing TEC were partially protected from cytolysis by activated OT-1 CD8þ CTL. (A) IFN-a, IFN-b or IFN-g
treated or untreated renal B6 TEC or EL-4 cells pulsed with 10 ng/ml of OVA257–264 or b-Gal497–504 peptide were co-incubated
with activated OT-1 CD8þ CTL as an E/T ratio 10:1 (1 105 of CTL to 1 104 of TEC per well) for CTL assay. After 4 h of incubation,
specific cytolysis of targets was measured with the CytoTox 96 non-radioactive cytotoxicity assay and calculated as described in
‘Materials and methods’. *P 0.05; **P 0.001, when compared with untreated TEC (Student’s t-test). (B) CTL assay was performed
by using IFN-a, IFN-b or IFN-g pre-treated or untreated, OVA257–264 peptide-pulsed B6 TEC as targets as described in (A), in the presence
or absence of anti-mouse PD-L1 mAb (10 mg/ml). TEC pulsed with b-Gal497–504 peptide was used as control. Data represent the mean %
lysis SD. One out of three independent experiments is shown. *P 0.05; **P 0.001, when compared with TEC without Ab blockade
(Student’s t-test).
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sponse.  Conclusion: Our data show that TGF-  changed the 
cellular phenotype and the expression of PD-L1 and CD40 
on TECs and enhanced the activity of OVA peptide-specific 
CD8+ T cells. TGF-  may thereby play an important role in 
the progression of renal tubulointerstitial damage in CD8+ 
T-cell-mediated renal diseases. 
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 Introduction 
 Transforming growth factor-  (TGF-  ) is a pleiotro-
pic cytokine involved in multiple physiological processes 
such as cell proliferation, wound healing and immune 
processes  [1] . Elevated expression of TGF-  is detected in 
many renal diseases. It has been shown that TGF-  plays 
a critical role in renal disorders such as IgA nephropathy, 
tubulointerstitial injury and acute and chronic renal al-
lograft rejection  [2–4] , and that blockade of TGF-  is 
beneficial in experimental kidney diseases  [5, 6] . During 
tubulointerstitial injury, inflammation and fibrosis are 
key events that may lead to chronic renal failure  [7] . TGF-
  is the most important regulator of both processes be-
cause it acts on the renal epithelium and on infiltrating 
immune cells. TGF-  induces a process known as epithe-
lial-to-mesenchymal transition (EMT) in renal tubular 
epithelial cells (TECs)  [8–10] . This complex process of 
 Key Words 
 Molecules, co-stimulatory   Cytotoxic T cells   Renal 
proximal tubular epithelial cells   Transforming growth 
factor-  
 Abstract 
 Background/Aim: TGF-  expression is increased in im-
mune-mediated and fibrotic renal diseases and modulates 
the tubulointerstitial T-cell response. We examined whether 
TGF-  changes the expression of PD-L1 and CD40 in the re-
nal proximal tubular epithelial cell (TEC), and whether the 
activation of CD8+ cytotoxic T cells (CTLs) is influenced by 
TGF-  treatment of TECs.  Methods: Murine TECs were treat-
ed with TGF-  or IFN-  . The expression of PD-L1 and CD40 
was examined with RT-PCR and flow cytometry. To investi-
gate if TGF-  treatment influenced the antigen presentation 
capacity of TECs, OT-1 CTLs were co-incubated with TGF-  -
treated, OVA 257–264  peptide-pulsed congeneic TECs. The cy-
totoxicity of OT-1 CTLs was estimated by their capacity to 
produce IFN-  and their cytolytic activity.  Results: TGF-  
treatment lead to a transition in morphology of renal TECs 
and downregulated the basal and the IFN-  -stimulated PD-
L1 expression in TECs. Interestingly, TGF-  treatment of TECs 
increased the constitutive and IFN-  -induced CD40 expres-
sion. In contrast to IFN-  which reduced the CTL activity, 
TGF-  treatment of TECs elevated the OVA-specific CTL re-
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transition includes loss of epithelial cell adhesion, disrup-
tion of tubular basement membrane and enhanced cell 
migration and invasion, which promotes renal fibrogen-
esis  [11] .
 Another function of TGF-  is the regulation of im-
mune responses. It directly affects, among others, prolif-
eration, differentiation and survival of T cells  [1] . It has 
been reported that a high amount of TGF-  promoted the 
recruitment of allogenic CD8+ T cells and increased the 
T-cell/TEC contact during acute rejection by upregula-
tion of the CD103 (   E    7  integrin) molecule on CD8+ T 
cells, which binds to E-cadherin on renal epithelial cells 
 [12] .
 Due to their expression of MHC class I and II mole-
cules and certain co-stimulatory molecules, renal TECs 
can behave as ‘non-professional’ antigen-presenting cells 
(APCs) and therefore are able to present foreign antigens 
to CD4+ and CD8+ T cells. The co-stimulatory molecule 
expression pattern on renal TECs depends on the sur-
rounding cytokine milieu. For example, the proinflam-
matory cytokine interferon-  (IFN-  ) enhances MHC 
class I and II molecules on renal TECs and also increases 
the expression of co-stimulatory molecules such as pro-
grammed death ligand 1 (PD-L1 or B7-H1) and inducible 
co-stimulator ligand (ICOS-L or B7RP1)  [13, 14] . PD-L1, 
a member of the B7 family, is widely expressed on lym-
phoid and non-lymphoid cells. Interaction of PD-L1 with 
its receptor programmed cell death 1 (PD-1) on T and B 
cells suppresses lymphocyte activation. We have previ-
ously reported that the IFN-  induced upregulation of 
PD-L1 on renal TECs inhibits antigen-specific T-cell re-
sponses in vitro  [14, 15] .
 The CD40-CD40L co-stimulatory pathway may also 
be critical in the interaction between renal TECs and T 
cells. CD40 belongs to the family of tumor necrosis factor 
receptors and is expressed on professional APCs, endo-
thelial cells, fibroblast and epithelial cells. Its ligand 
CD154 (CD40L) is mainly found on activated T cells. The 
interaction between both molecules is responsible for the 
maturation of APCs (e.g. dendritic cells) and the priming 
of T-cell responses. CD40 is weakly expressed on renal 
epithelial cells under healthy conditions and is increased 
during lupus glomerulonephritis, rejection and murine 
chronic proteinuria  [16–18] . The interaction of renal 
CD40 with CD40L on infiltrating T cells influences the 
T-cell response as well as the function of renal TECs. On 
the other hand, the CD40-CD40L pathway is also in-
volved in the development of fibrosis in several organs 
such as lung and liver  [19] . Stimulation of CD40 on fibro-
blasts by CD40L-bearing T cells and mast cells leads to 
proliferation of fibroblasts, production of proinflamma-
tory mediators and extracellular matrix components by 
fibroblasts  [19] . Pontrelli et al.  [20] showed that ligation 
of CD40 on renal TECs has not only proinflammatory 
but also profibrotic effects.
 Despite its well-defined role in renal fibrosis, the func-
tion of TGF-  on the regulation of co-stimulatory and 
co-inhibitory molecule expression on renal TEC is large-
ly unknown. Thus, we investigated the effect of TGF-  
on the expression of the co-inhibitory molecule PD-L1 
and on the co-stimulatory molecule CD40 on murine pri-
mary TECs and TEC cell line C1.1. TGF-  -treated TECs 
were exposed to antigen-specific OT-1 CD8+ T cells to 
explore their cytotoxic response. The effects of TGF-  
stimulation on renal TECs were compared to the influ-
ences of its antagonistic cytokine IFN-  which is a potent 
inducer of PD-L1 but counteracts the profibrotic action 
of TGF-  on renal TECs  [21] .
 Methods 
 General Reagents 
 Cell culture reagents were obtained from Invitrogen (Gaith-
ersburg, Md., USA) and Sigma (St. Louis, Mo., USA). Recombi-
nant mouse IFN-  and human TGF-  were purchased from R&D 
Systems (Oxford, UK). Anti-mouse PD-L1 and CD40 monoclonal 
antibodies (mAbs) were obtained from eBioscience (San Diego, 
Calif., USA). Biotin-conjugated anti-mouse H-2K k  was obtained 
from BD Biosciences (San Jose, Calif., USA). Chicken ovalbumin 
peptide 257–264 (OVA 257–264 , amino acid sequence SIINFEKL) 
was purchased from Proimmune (London, UK). An H-2K b  re-
stricted   -galactosidase peptide 497–504 (  -Gal 497–504 , amino 
acid sequence ICPMYARV) was used as a control. Anti-mouse 
CD8a (Ly-2) MACS microbeads were obtained from Miltenyi Bio-
tec (Bergisch Gladbach, Germany).
 Animals and Cell Cultures 
 OT-1 mice  [22] were obtained from the Jackson Laboratory 
(Bar Harbor, Me., USA) and C57BL/6 (B6) mice were purchased 
from Harlan (Horst, the Nertherlands). All animals were main-
tained in the animal facility at the Irchel Campus of the Univer-
sity of Zürich, Switzerland. The study protocol was approved by 
the regulatory commission for animal studies of the Canton of 
Zürich, Switzerland. Primary cultures of murine renal proximal 
TECs and a SV40-transformed murine renal proximal TEC line 
C1.1 were prepared and cultured as described  [23] .
 RT-PCR Analysis 
 Total RNA was extracted from the indicated cell cultures with 
RNeasy  mini kit (Qiagen, Valencia, Calif., USA). All samples 
were quantified by the measurement of the optical density at 260 
nm, and 1   g of RNA was amplified using OneStep RT-PCR kit 
(Qiagen). Primer sequences of PD-L1 and CD40 were determined 
as previously described  [14] . PD-L1 and CD40 mRNA levels were 
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normalized by the corresponding GAPDH mRNA levels. Reac-
tion mixtures were separated on 1.5% agarose gels containing 
ethidium bromide, and bands were detected under UV light and 
analyzed with the Bio-Image System Chemidoc TM  XRS (Bio-Rad, 
Hercules, Calif., USA). Densitometry analysis was performed 
with the Quantity One Software 4.6.1 (Bio-Rad Laboratories, 
Inc).
 Flow Cytometry Analysis 
 The TEC line C1.1 and primary cultures of renal TECs were 
stimulated with different concentrations of TGF-  alone or in 
combination with IFN-  for 48 h. Cells were harvested by light 
trypsinization, washed and suspended in PBS containing 2% FBS 
and 0.1% sodium azide. After incubating with primary mAbs for 
45 min on ice, cells were washed twice and incubated with the ap-
propriate FITC-conjugated secondary Ab for 30 min. Cells were 
then washed and analyzed using a FACScan flow cytometer and 
the Cell Quest TM  software (Becton Dickinson).
 Determination of Morphology of TECs 
 Primary renal TECs were treated either with TGF-  or IFN-  
for 6 and 48 h. The morphology of TECs was determined with an 
Axiovert 200M microscope (Carl Zeiss AG, Germany) and ana-
lyzed with AxioVision software (Carl Zeiss AG, Germany).
 Isolation of CD8+ T Cells from OT-1 Mice 
 Spleen and lymph nodes were harvested from 8- to 16-week-
old naive OT-1 mice. CD8+ cells were isolated using anti-mouse 
CD8a (Ly-2) MACS microbeads according to the manufacturer’s 
protocol. The freshly isolated OT-1 CD8+ T cells were either used 
immediately for antigen presentation assays or were activated in 
vitro by stimulation with B6 splenocytes pulsed with 0.1   g/ml of 
OVA 257–264  peptide. Cells were incubated in DMEM medium sup-
plemented with 5   M 2-mercaptomethanol, 1% HEPES, 1,000 U/
ml penicillin, 100   g/ml streptomycin and 10% FBS. After 6 days 
of stimulation, activated OT-1 CTLs were used for CTL assays.
 Antigen Presentation of Renal B6 TECs to OT-1 CD8+ T Cells 
 To study the antigen presentation of the H-2K b -restricted pep-
tide OVA 257–264  by congeneic primary TECs to OT-1 CD8+ T cells, 
B6 primary TECs were pretreated with IFN-  (100 U/ml) or TGF-
  (2 ng/ml) for 48 h. Cells were washed to remove excess cytokines 
and were harvested by light trypsinization. The cells were then 
pulsed with 0.1   g/ml of OVA 257–264  peptide or the control H-2K b -
restricted   -Gal 497–504  peptide for 1 h at 37  °  C. After washing, 
TECs were counted and seeded in 96-well U-bottomed cell cul-
ture plates (2  ! 10 4 /well) in DMEM medium supplemented with 
5% FBS, 100 U/ml of penicillin and 100   g/ml of streptomycin. 
The resting OT-1 CD8+ T cells were added to TEC cultures (2  ! 
10 5 /well) and were co-incubated at 37  °  C. After 24 h, supernatants 
from co-cultures were collected and analyzed for IFN-  content 
using a mouse IFN-  -specific ELISA kit (OptEIA TM  mouse IFN-  
kit, BD Pharmingen).
 Cytotoxicity by Activated OT-1 CD8+ CTLs to B6 TECs 
 To measure the antigen-specific cytolysis of renal TECs by 
CTLs, activated OT-1 CD8+ CTLs were added to TGF-  - or IFN-
  -treated OVA 257–264  peptide-loaded B6 TECs in 96 U-bottomed 
cell culture plates at effector/target ratios of 10:  1 or 5:  1 as indi-
























































 Fig. 1. RT-PCR analysis of PD-L1 and CD40 mRNA expression in 
renal TEC after treatment with TGF-  .  a Agarose gel stained with 
ethidium-bromide. C1.1 cells were treated with different concen-
trations of TGF-  or IFN-  (100 U/ml) for 6 h or without cytokine 
treatment. GAPDH was used as a housekeeping gene.  b Densi-
tometry analysis of the agarose gel showed in  a was performed. 
The density of the PD-L1/ GAPDH ratio was calculated as the fold 
density of the untreated mRNA level of C1.1 cells. Data represent 
the mean ratio of each sample  8 SD from two independent load-
ings of the same RT-PCR sample. 
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lected from each well to measure the amount of lactate dehydro-
genase (LDH) using the CytoTox 96  non-radioactive cytotoxic-
ity assay kit (Promega) according to the manufacturer’s protocol. 
The percentage of target lysis was calculated as: % lysis = 100  ! 
(experimental LDH release – spontaneous LDH release of tar-
gets – spontaneous LDH release from T cells)/(maximum LDH 
release – spontaneous LDH release of targets).
 Statistics 
 All experiments were performed at least three times. Results 
from IFN-  ELISA or CTL assays are expressed as means  8 SD 
of triplicate determinations from the representative experiments 
that gave rise to similar results. Statistical analysis was performed 
using unpaired Student’s t test. Significance was accepted at p  ^  
0.05.
 Results 
 TGF-  Treatment Altered the Expression of PD-L1, 
CD40 and MHC Class I Molecules in Renal TECs 
 The TEC line C1.1 and primary TECs were stimu-
lated with different concentrations of TGF-  to deter-
mine the mRNA and surface expression of PD-L1, CD40 
and MHC class I molecules. Untreated and IFN-  -stim-
ulated TECs were used as controls.  Figure 1 shows that 
constitutive PD-L1 and CD40 mRNAs were detected in 
C1.1 cells and primary TECs without cytokine stimula-
tion. IFN-  treatment led to the increase in PD-L1 
mRNA, whereas only a slight change in CD40 mRNA 
Untreated







































IFN- + TGF-  (ng/ml):
2nd Ab
 Fig. 2. Expression of surface PD-L1, CD40 and MHC class I mol-
ecules on renal TECs after TFG-  treatment. C1.1 cells stimu-
lated with different concentrations of TGF-  for 48 h or without 
treatment were stained with anti-mouse PD-L1, CD40 and MHC 
class I mAbs for flow cytometric analysis. Results are representa-
tive of 3 independent experiments. 
 Fig. 3. TGF-  altered the IFN-  -induced surface expression of 
PD-L1, CD40 and MHC class I molecules on renal TECs. C1.1 
cells were stimulated with different concentrations of TGF-  for 
48 h in the presence of IFN-  (100 U/ml) or without treatment. 
Cells were then stained with anti-mouse PD-L1, CD40 and MHC 
class I mAbs for flow cytometric analysis. Results are representa-
tive of 3 independent experiments. 
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was observed with IFN-  treatment. A decrease in PD-
L1 mRNA was observed after TGF-  stimulation at 
concentrations of 0.5–2.5 ng/ml. Interestingly, treat-
ment with TGF-  strongly enhanced the CD40 mRNA 
level in renal TECs ( fig. 1 ). Flow cytometry analysis re-
vealed a strong increase in CD40 on the renal TEC sur-
face after TGF-  treatment but no surface expression of 
PD-L1 on TECs could be detected after TGF-  treat-
ment ( fig. 2 ). In addition, TGF-  treatment slightly 
downregulated the constitutive MHC class I expression 
on renal TECs.
 TGF-  Downregulated IFN-  -Induced Upregulation 
of PD-L1 and MHC Class I Molecules and Increased 
CD40 Expression 
 To determine whether inflammatory-mediated up-
regulation of PD-L1 and CD40 can be altered by TGF-  
treatment, renal TECs were treated with TGF-  in the 
presence of IFN-  . As shown in  figure 3 , TGF-  stimula-
tion downregulated the IFN-  -induced upregulation of 
PD-L1 and MHC class I molecules in a dose-dependent 
manner. Very interestingly, TGF-  treatment further in-
creased the IFN-  -induced CD40 upregulation on renal 
TECs ( fig. 3 ). These results indicated that TGF-  is a 
modulator of IFN-  -induced PD-L1 and MHC class I 
molecule expression and a strong stimulus to increase 
CD40 expression on renal TECs.
 TGF-  Treatment Induced a Change in Morphology 
in Renal TECs 
 TGF-  is the main inducer of EMT in renal epithelial 
cells  [8] . To show that TGF-  was also profibrotic in our 
cell culture system, primary renal TECs were treated with 
TGF-  or IFN-  . As shown in  figure 4 , untreated renal 
TECs were closely attached to each other and displayed a 
normal cobble-stone morphology ( fig. 4 a). Stimulation 
with IFN-  for 48 h did not change the morphology of 
renal TECs ( fig. 4 b). Although there was no visible change 
in renal TECs after treatment with TGF-  for 6 h ( fig. 4 c), 
alterations in the morphology of TECs were observed 
within 24 h (data not shown). The 48-hour incubation 
with TGF-  induced a remarked morphological change 
in renal TECs ( fig. 4 d). The confluent monolayer was dis-
rupted as the cells detached from the bottom of the cell 
dish. The cells became elongated, formed filopodia and 
showed a spindle-shaped, fibroblastic morphology. Since 
the change in co-stimulatory molecule expression reached 
a plateau level at 48 h, we used this time point for the sub-
sequent experiments.
 TGF-  Stimulation of B6 TECs Enhanced Their 
Capacity to Activate Naive OT-1 CD8+ T Cells 
 To determine if the antigen-presenting capacity of re-
nal B6 TECs to OVA 257–264  peptide-specific OT-1 CD8+ 
T cells was influenced by TGF-  stimulation of TECs, 
renal B6 TECs were pretreated with TGF-  or IFN-  and 
loaded with OVA 257–264  peptide or the irrelevant peptide 
  -Gal 497–504 . The activation of naive OT-1 CD8+ T cells 
was measured by their IFN-  production. The antigen-
presenting capacity of TGF-  -stimulated TECs differed 
from the ability of untreated and IFN-  -treated TECs 
( fig. 5 a). A significant increase in IFN-  was measured 
after TGF-  stimulation of TECs compared to untreated 
and IFN-  treated TECs. IFN-  -treated TECs even 
showed a reduced capacity to stimulate OT-1 CD8+ T 
cells to produce IFN-  compared to untreated TECs. 
TECs loaded with the irrelevant peptide   -Gal 497–504  
failed to induce production of IFN-  by OT-1 CD8+ 
T cells. Thus, TGF-  stimulation of renal TECs influ-
enced their capacity to activate antigen-specific OT-1 
CD8+ T cells.
 TGF-  -Treated B6 TECs Were More Susceptible to Be 
Killed by Activated OT-1 CD8+ T Cells 
 Next we examined the effect of TGF-  -stimulated re-
nal TECs on the cytotoxicity of activated OT-1 CD8+ T 
cells. For this purpose, activated OT-1 CD8+ T cells were 
incubated with renal B6 TECs pretreated with TGF-  
 Fig. 4. Representative photomicrographs of murine B6 primary 
renal TECs after stimulation with IFN-  (100 U/ml) or TGF-  
(2.5 ng/ml) for 6 or 48 h.  a Untreated.  b IFN-  48 h.  c TGF-  6 h. 
 d TGF-  48 h.  ! 20. 
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or IFN-  and loaded with OVA 257–264  peptide or   -
 Gal 497–504  to measure the lysis of TECs. The cytotoxicity 
of OVA peptide-specific OT-1 CD8+ T cells to TGF-  -
treated renal B6 TECs was significantly increased at pep-
tide concentrations of 100 and 10 ng/ml compared to the 
untreated and IFN-  treated TECs ( fig. 5 b, c). IFN-  -
stimulated renal TECs were partially protected from the 
lysis induced by OT-1 CD8+ cytotoxic T cells. OT-1 CD8+ 
T cells did not kill B6 TECs incubated with the irrelevant 
peptide   -Gal 497–504 . In summary, these data show that 
the OT-1 CD8+ T-cell response was antigen-specific and 
that TGF-  -treated TECs significantly enhanced the 
OT-1 CD8+ activity.
 Discussion 
 It is well known that TGF-  is widely involved in dif-
ferent kinds of renal diseases  [5, 24] and that it elicits re-
nal fibrogenesis by inducing EMT in renal epithelial cells 
 [8, 9] . However, the effect of TGF-  on co-stimulatory 
molecule expression by renal TECs and its implications 
in TEC/CD8+ T-cell interaction has so far not been fully 
investigated. In the present study, we show that, beside 
the transition in morphology of renal TECs, in vitro stim-
ulation of renal TECs with TGF-  downregulated the 
constitutive PD-L1 mRNAs and the IFN-  -induced PD-
L1 surface expression. In contrast, CD40 mRNA and sur-
face protein were clearly enhanced after TGF-  treat-
ment. In addition, the antigen-specific OT-1 CD8+ T-cell 
activation was increased by using TGF-  -treated TECs as 
antigen-presenting cells/targets. Thus, in addition of a 
critical profibrotic factor, TGF-  also affects co-stimula-
tory molecule expression on renal TECs under our in vi-
tro experimental conditions.
 Our study complements former studies that investi-
gated the effect of TGF-  on co-stimulatory molecule ex-
pression on renal TECs. Banu and Meyers  [25] showed 
that TGF-  downregulated IFN-  -induced expression of 
MHC class II and B7.1 on primary murine renal TECs. In 
that case, TGF-  stimulation of TECs decreased their an-
tigen-presenting capacity and lowered the production of 
IL-4 by a CD4+ Th2 clone. In agreement with that study, 
we also observed that TGF-  treatment reduced the con-
stitutive and IFN-  -induced MHC class I (and PD-L1) 
expression on renal TECs. However, our results that TGF-
  -treated TECs increased OT-1 CD8+ T-cell responses 
are controversial to their findings. This difference may be 


































































 Fig. 5. Higher OVA 257–264  specific OT-1 CD8+ T-cell responses 
were induced by TGF-  -treatment of B6 renal TECs. B6 renal 
TECs were pretreated with TGF-  (2 ng/ml), IFN-  (100 U/ml) 
for 48 h or untreated. TECs were then loaded with 0.1   g/ml 
OVA 257–264  or the same concentration of an irrelevant   - 
Gal 497–504  peptide and incubated with naive OT-1 CD8+ T cells 
for 24 h to determine the IFN-  production in the supernatants 
with ELISA ( a ) or with activated OT-1 CD8+ T cells for 4 h to 
measure the cytolysis of the targets ( b ). In another experimental 
setting, different concentrations of OVA 257–264  peptide were 
pulsed with renal TECs pretreated as described above and were 
incubated with activated OT-1 CD8+ T cells (effector/target ratio 
5:  1) for the cytotoxic assay ( c ).  * p  ^  0.05;  * * p  ^  0.01;  * * * p  ^  
0.001 Student’s t test. 
46
 Starke  /Wüthrich  /Waeckerle-Men  
 
Nephron Exp Nephrol 2007;107:e22–e29e28
 Co-stimulatory/co-inhibitory signals effectively regu-
late T-cell activation and tolerance. It is well accepted that 
the CD40/CD40L co-stimulatory pathway provides a 
positive signal to increase T-cell responses  [26] , and the 
CD40/CD40L interaction is thought to be involved in the 
regulation of interstitial infiltration in the kidney  [18, 27] . 
Rogers et al.  [28] reported that renal TECs expressing 
CD40 were capable of stimulating the proliferation of 
CD4+ T cells. On the other hand, the PD-L1/PD-1 path-
way provides the negative signal to downregulate CD4+ 
and CD8+ T-cell responses  [14, 15] . The downregulation 
of PD-L1 and upregulation of CD40 on renal TECs by 
TGF-  treatment observed in the current study therefore 
may explain the increased OT-1 CD8+ T-cell activation. 
As shown previously, TECs with high PD-L1 surface ex-
pression were protected from killing by OT-1 CD8+ T 
cells  [15] . In addition, we also observed that blocking 
CD40 on the TEC surface by anti-mouse CD40 mAbs 
slightly decreased OT-1 CD8+ T-cell responses (data not 
shown), although the change was not statistically signifi-
cant compared with the untreated TECs. Our hypotheses 
for this phenomenon might be that the CD40 expression 
on TECs plays a role in fibrosis initiation (discussed 
 below). Another possibility is that the CD40/CD40L  co-
stimulatory pathway would be more crucial for the 
 activation of CD4+ T cells than for CD8+ T cells  [29] . Fur-
ther studies may be needed to clarify whether TGF-  -
treated renal TECs would also be able to increase the 
CD4+ T-cell activity.
 The functional role of renal TEC-expressed CD40 is 
still not fully understood. Despite its well-know co-stim-
ulatory function on professional APCs, tissue-expressing 
CD40 is involved in the development of fibrosis  [19] . Pon-
trelli et al.  [20] showed that soluble CD40L played a key 
role in interstitial fibrosis by increasing the expression of 
the profibrotic peptide plasminogen activator inhibitor-1 
in human TECs in vitro. Another study demonstrated 
that blockade of CD40/CD40L interactions in murine 
adriamycin nephrosis attenuated not only the interstitial 
inflammation but also the structural injury  [18] . Taken 
together, we assume that the TGF-  -increased CD40 ex-
pression on TECs may function not only as a co-stimula-
tory molecule but also be involved in amplifying the 
TGF-  -induced fibrogenesis in the kidney.
 In summary, we show that TGF-  not only induced 
structural alterations but also regulated co-stimulatory 
molecule expression on renal proximal epithelial cells 
with functional consequences on their antigen-present-
ing capacity. Besides its crucial and well-defined influ-
ence on renal fibrosis, TGF-  may additionally play an 
important role in the progression of renal tubulointersti-
tial damage in CD8+ T-cell-mediated renal diseases.
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The in vivo role of the co-inhibitory molecule PD-L1 in modulating T cell responses in TIN 
has not been elucidated yet. To investigate the role of PD-L1 in TEC/T cell interactions in 
vivo, we attempted to establish an antigen-specific model of TIN in RIP-mOVA transgenic 
mice, which express the ovalbumin (OVA) antigen in the pancreas and the kidney. To induce 
inflammation and T cell infiltration in kidneys of RIP-mOVA mice, two experimental 
strategies were tested. The first one was to directly transfer activated OVA peptide-specific 
OT-1 CD8+ T cells (CTLs) into RIP-mOVA mice (CTL transfer strategy). These OVA-
specific CD8+ T cells should attack their targets, including OVA-expressing TECs, to induce 
a renal injury. In the second strategy RIP-mOVA mice were immunized with OVA protein 
and peptide to induce OVA-specific T cell responses in vivo (immunization strategy) against 
the local “self”-antigen OVA in the kidney and in the pancreas of RIP-mOVA mice. 
 
Diabetes occurred as a consequence of pancreatic islets injury in 70-100% of the RIP-mOVA 
mice that were injected with activated CTLs. Both adoptive CTL transfer and the 
immunization strategies induced a marked upregulation of MHC class II and PD-L1 
expression on renal TECs in RIP-mOVA mice. The transfer of high amounts of OVA-specific 
OT-1 CTLs (10x106) resulted in a rapid and moderate CD8+ T cell accumulation in the renal 
cortex within 5 days. In contrast, a mild T cell infiltration in the cortical tubulointerstitial 
space was detected in mice immunized with OVA antigens after two and three weeks. In 
addition, re-stimulation of T cells isolated from spleens of immunized RIP-mOVA mice in 
vitro gave rise to OVA antigen-specific CD4+ and CD8+ T cell responses, indicating that the 
immunization with “self-antigens” did not induce an immune tolerance. After adoptive 
transfer of OVA-specific CTLs anti-PD-L1 monoclonal antibodies were administrated into 
the mice to try to inhibit the PD-1/PD-L1 pathway in vivo. However, no significant influence 
on the onset of diabetes and kidney infiltration has been observed in the current experimental 
setting.  
 
Taken together, both strategies induced kidney inflammation, and the PD-1/PD-L1 pathway 
was activated in the antigen-specific RIP-mOVA model. RIP-mOVA mice represent a useful 
model to investigate the expression profile and the role of molecules induced on TECs during 




PD-L1 on parenchymal tissues plays a protective role in limiting auto-reactive T cell 
responses, as already described in the introduction section 3.2. We have shown in several 
studies that PD-L1 is expressed on murine TECs in vitro and in vivo and that the enhancement 
of the PD-1/PD-L1 pathway leads to the inhibition of CD4+ and CD8+ T cell responses in 
vitro (Chapter 1-3, (1)). However, the in vivo role of renal tubular epithelial PD-L1 in 
modulating T cell responses in TIN has not been explored yet. Since there are not many 
animal models of TIN to study antigen-specific T cell-mediated nephritis, we attempted to 
establish an antigen-specific model of TIN using RIP-mOVA transgenic mice. 
 
RIP-mOVA mice are on a C57BL/6 (H2-Kb) background and express a membrane-bound 
form of ovalbumin (mOVA) consisting of the residues 139-385 from mature OVA which is 
linked to the cytoplasmic and signal/anchor domain of the human transferrin receptor. The 
cDNA encoding the mOVA fusion protein is under the control of the rat insulin promoter 
(RIP). RIP-mOVA mice express mOVA in pancreatic β cells, kidney proximal tubular cells 
(Figure 1) and to a lower extent in the testes and the thymus (2). It has previously been 
reported that the transfer of OVA-peptide specific CD8+ T cells into these mice induces 
antigen-specific tissue injury in the pancreas and the kidney. 
 
Figure 1: Expression of OVA in RIP-mOVA mice. 
Immunohistochemistry performed on (A) kidney and (B) pancreas 
sections. The arrow in A indicates a proximal tubule originating from a 










The OVA-specific CD8+ T cells used in these experiments are derived from T cell receptor 
(TCR) transgenic OT-1 (OVA-specific, class I-restricted TCR transgenic) mice. This TCR 
recognizes the ovalbumin residues 257-264 (SIINFEKL) in the context of H2-Kb (C57BL/6 
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background). OT-1 mice exhibit the same amount of total T cells as non-transgenic littermates 
but OT-1 T cells are shifted towards the CD8+ subset (3). 
 
The adoptive transfer of 5x106 naïve OVA-peptide specific OT-1 CD8+ T cells into RIP-
mOVA mice leads to the homing, accumulation and activation of these cells in the draining 
lymphnodes (LNs) of the OVA-expressing tissues, namely the renal and pancreatic LNs (2). 
Kurts et al. have shown that these auto-reactive and in vivo activated OT-1 CD8+ T cells are 
deleted in the draining LNs of OVA-expressing tissues (4). However, the adoptive transfer of 
a high number, i.e. 10x106, of in vitro activated OT-1 CD8+ T cells into RIP-mOVA mice 
leads to varying degrees of kidney infiltration, ranging from no infiltrates to dense 
mononuclear infiltration of the whole cortex. CD8+ T cells have been found to accumulate 
next to the mOVA-expressing tubules (5). Beside the kidney infiltration, a destruction of 
pancreatic islet cells have appeared at day 2-3 after transfer, manifesting in diabetes. 
Importantly, the adoptive transfer of high numbers (up to 20x106) of naïve as opposed to 
activated OT-1 CD8+ T cells has not resulted in kidney infiltration whereas development of 
diabetes has always been observed even after the injection of low numbers of naïve OT-1 
CD8+ T cells (5). 
 
Immunization with self antigens has turned out to be an efficient strategy to induce 
autoimmune diseases in mice. For example, in experimental autoimmune encephalomyelitis 
(EAE), the animal model for MS, the injection of myelin components, e.g. myelin basic 
protein (MBP) and proteolipid protein (PLP) in complete Freud’s adjuvant has induced 
antigen-specific Th1 cells that infiltrate and accumulate in the central nervous system. There, 
T cells recognize their antigen and produce IFN-γ leading to inflammation and destruction of 
myelin which results in paralysis of the mice (6, 7). Thus, the injection of OVA-antigens into 
RIP-mOVA mice may be a promising strategy to induce an autoimmune response in the 
kidney. 
 
The purpose of the present study has been to adapt this RIP-mOVA animal model to study  
1) the characteristics of tubulointerstitial inflammation, 
2) the role of the PD-1/PD-L1 pathway in vivo and  
3) the development of strategies to influence autoimmune renal injury. 
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Two experimental strategies have been tested. 
 
The first one was the adoptive transfer of in vitro activated OVA peptide-specific OT-1 CD8+ 
T cells into RIP-mOVA mice (CTL-transfer strategy). According to the literature, after the 
transfer of high amounts of CTL, i.e. 10x106 cells we expected that the OVA-specific OT-1 
effector CTLs will find their targets, i.e. OVA-expressing renal tubular epithelial cells, and 
induce renal tubular inflammation and injury. 
 
The second strategy was designed to immunize RIP-mOVA mice with OVA protein and 
peptide (immunization strategy). The aim was to induce an autoimmune response in RIP-
mOVA mice against the kidney by injection of “self-antigens”, e.g. OVA257-264 peptide and 
OVA protein. Professional APCs such as DCs and macrophages will take up the injected 
antigens, process and present them to CD4+ and CD8+ T cells. This should lead to an 
activation and expansion of auto-reactive CD4+ and CD8+ T cells and to an induction of 
OVA-specific polyclonal immune responses in vivo. The in vivo primed OVA-specific CD4+ 
and CD8+ T cells should then infiltrate into the kidney and the pancreas. 
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4.3. Materials and methods 
 
General reagents and antibodies 
Cell culture reagents were purchased from Invitrogen (Gaithersburg, USA) and Sigma (St. 
Louis, USA). Anti-PD-L1 (αPD-L1) monoclonal antibody (Ab) for in vivo injection was 
obtained from hybridoma cell culture supernatants from the cell line MIH5 which was 
obtained from RIKEN Cell bank with the permission of Prof. Miyuki Azuma, Tokyo Medical 
and Dental University, Japan. Purification of the Ab from MIH5 cell culture supernatants was 
performed by Dr. David Hacker, Protein Expression Core Facility, EPFL-SV, Lausanne, 
Switzerland. The Abs were diluted in PBS. As isotype control, IgG from rat serum (Sigma-
Aldrich, Germany) dissolved in PBS was used. 
 
Purified rat anti-mouse MHC class II, CD4 (clone L3T4), CD8a (Ly-2, clone 53.6.7) and PD-
L1 (clone MIH5) used for immunofluorescence were purchased from eBiocience (San Diego, 
USA). As secondary antibody for the immunofluorescence Cy™3-conjugated mouse anti-rat 
IgG- from Jackson ImmunoResearch (USA) was used. Anti-CD3 antibody (clone: CD3-12, 
rat anti-human, cross-reactive with mouse) employed for immunohistochemistry was obtained 
from Serotec (Oxford, UK). 
 
Mice 
RIP-mOVA and OT-1 mice were obtained from the Jackson Laboratory (Bar Harbor, Me., 
USA). C57BL/6 (B6) mice were purchased from the breeding facility of the University of 
Zürich (LTK Füllinsdorf, Basel, Switzerland). All mice were bred and maintained at the 
animal facility of the Institute of Physiology, University of Zürich-Irchel, Switzerland. The 
animal experimental protocols were approved by the Regulatory Commission for Animal 
Studies at the Canton of Zürich, Switzerland. RIP-mOVA (Tg/+), non-transgenic littermate 
control (non-Tg) and B6 mice were used at the age from 8-18 weeks for all in vivo 
experiments. 
 
Screening for the presence of the transgene in RIP-mOVA and OT-1 mice 
Genotyping of RIP-mOVA mice was performed by isolating DNA from a tail tip with the 
DNAeasy® Blood&Tissue kit (Qiagen, Hilden, Germany) according to the manufactures` 
protocol. Primers and PCR cycle conditions were taken from Kurts et al (2). Peripheral blood 
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of OT-1 mice was screened for OVA-peptide specific CD8+ T cells by FACS analysis as 
described below. 
 
In vitro activation and adoptive transfer of OT-1 CD8+ T cells 
CD8+ T cells were isolated from spleens of naïve OT-1 mice by positive selection with anti-
mouse CD8a (Ly-2) MACS microbeads obtained from Miltenyi Biotec (Bergisch Gladbach, 
Germany). 1x106 OT-1 CD8+ T cells were activated in vitro by stimulation with 4x106 CD8- 
splenocytes pulsed with 1 µg/ml of chicken ovalbumin peptide (OVA 257–264, amino acid 
sequence SIINFEKL, Proimmune, London, UK). Cells were incubated in IMDM medium 
supplemented with 5 µM 2-mercaptoethanol, 0.05mg/ml gentamycin and 10% FBS. After 3-5 
days of stimulation activated OT-1 CD8+ T cells were injected intravenously (i.v.) into RIP-
mOVA, non-transgenic littermate controls or B6 mice.  
 
Treatment with anti-PD-L1 antibody (αPD-L1) in vivo 
αPD-L1 was injected intraperitonially (i.p.) into RIP-mOVA and B6 mice on day 1 and 3 after 
adoptive transfer of 2.5x106 or 10x106 OT-1 CD8+ T cells. 200 µg of Ab was injected each 
time. As controls, groups of RIP-mOVA and B6 mice were treated with PBS or isotype 
control (200µg, rat IgG) at the same time after adoptive transfer. 
 
Immunization protocol 
RIP-mOVA (Tg/+), non-transgenic controls (non-Tg) and B6 mice were immunized 
subcutaneously in the base of the tail with 100 µg albumin from chicken egg white (Sigma-
Aldrich, St. Louis, USA) and 50 µg OVA257–264 emulsioned in the incomplete Freud’s 
adjuvant (IFA, Sigma-Aldrich, St. Louis, USA ). Mice were either immunized once (day 0), 
twice (day 0 and 7) or three times (day 0, 7 and 14), respectively. The mice were sacrificed on 
different time points after immunization, e.g. on day 6, 14, 20 and 30.  
 
Measurement of glucose in urine and blood 
The disease progression, specifically the onset of diabetes, was determined by daily 
measurement of glucose levels in the urine and/or the blood. Combur3Test® or Combur10Test® 
M (Roche, Basel, Switzerland) were used to analyze glucosuria. Glucose levels between 2.8-
55 mmol/l could be detected by these urine strips. Blood glucose levels were determined with 
Ascensia® CONTOUR® (Bayer Schweiz AG, Zürich, Switzerland) and were measured twice 
per day in experimental mice after CTL transfer. 
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 Insulin treatment 
RIP-mOVA mice injected with OT-1 CD8+ T cells were treated with insulin (Actrapid® or 
Levemir® Penfill® 3, both novo nordisk®) when glycemia was higher than 8 mmol/l. Mice 
received 0.5 U/kg Actrapid® twice per day or Levemir® Penfill® 3 once per day. 
 
Organ removal 
At the end of the experiments mice were sacrificed by cervical dislocation and organs were 
removed for further analysis. The spleen was harvested for FACS analysis and in vitro 
experiments. Each kidney was divided into 2 pieces. 2 kidney pieces were snap frozen in 
isopentan (Fluka, Germany) in liquid nitrogen and 1 piece was fixed in formalin. All three 
were used for histological examination either on cryopreserved or formalin fixed tissue. The 
last one was transferred into RNA later® (Ambion, USA) for RNA isolation. The pancreas 
was either fixed in formalin for analysis of histology or stored in RNA later.  
 
Analysis of histology  
Haematoxylin and eosin (H&E), Period acid-Schiff (PAS) and CD3 staining were performed 
on formalin-fixed, paraffin-embedded kidney samples and done by Stephan Segerer. Staining 
of CD3 positive cells was performed as described (8). The tubulointerstitial T cell infiltrate 
was assessed by counting CD3 positive cells in 15 high power fields (HPFs) and by 
calculating the mean CD3 infiltrating cells per HPF.  
Cryo-preserved kidneys were cut into 6 µm sections (microtome, Leica CM3050 S) and 
placed on Superfrost® Plus slides. The slides were fixed in ice-cold acetone for 10 min and 
then washed in PBS. The following incubations steps were performed in a wet chamber. The 
slides were blocked for 1 h in 5% goat serum diluted in PBS and then incubated overnight at 
4°C with primary antibodies against mouse MHC class II, PD-L1, CD8 and CD4 diluted in 
PBS containing 1% BSA. Next day, the slides were washed in PBS for three times and stained 
with the secondary Ab and DAPI (4’,6-Diamidin-2’-phenylindoldihydrochlorid) for 1 h at RT 
in the dark. After washing, slides were covered with ProLong® Gold (Invitrogen, USA) and 
analyzed by microscope (Zeiss Axiovert 200M, Germany). 
 
FACS analysis 
OVA-peptide specific CD8+ T cell population in experimental mice after CTL transfer was 
measured in splenocytes with the Pro5 MHC Pentamer-PE against SIINFEKL (Proimmune, 
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London, UK) according to the manufacture’s protocol. CD8+ T cells were stained with CD8-
FITC (eBioscience, San Diego, USA).  
 
Measurement of OVA-antigen specific T cell responses 
Antigen-specific CD8+ T cell response: 
CD8+ T cells were isolated from spleens and LNs from immunized RIP-mOVA, non-
transgenic littermates and B6 mice with anti-mouse CD8a (Ly-2) MACS microbeads as 
described above. Part of the CD8 negative cell fraction was used as APCs and was pulsed 
with 1 µg/ml OVA257–264 for 1h at 37°C. 2x106 CD8+ T cells were then stimulated with 3x106 
CD8- cells loaded with or without OVA257–264 in 24-well plates.  After 48 h co-culture the 
supernatant was collected to measure the IFN-γ production by re-stimulated CD8+ T cells 
using mouse IFN-γ specific ELISA (BD OptEIA™, BD Biosciences, San Diego, USA). 
 
Antigen-specific CD4+ T cell response: 
The other part of the CD8- cells from spleen and LNs were used to determine the OVA-
specific CD4+ T cells response. 5x105 CD8- negative cells were stimulated with OVA protein 
at concentrations of 100, 20, 4, 0.8, and 0.16 µg/ml for 72 h in triplicates in 96-well plates. As 
a positive control for CD4+ T cell proliferation, cells were stimulated with 2 µg/ml ConA at 
the same time. The CD4+ T cell proliferation was measured with the non-radioactive 
colorimetric CellTiter 96® AQueous One Solution Cell Proliferation Assay kit (Promega) 
according to the manufacturer’s protocol. Results were presented as the mean value of the OD 
at 490 nm. 
 
Statistical analysis 
All in vitro experiments were performed as duplicate or triplicate. The preparation of the 
graphs and the statistical analysis was performed with GraphPad Prism Version 4 (GraphPad 
Software, Inc; La Jolla, USA). Mann Whitney test was used to compare the different groups 
of mice. A significant difference in the onset of diabetes development was tested with the 




4.4.1. CTL transfer strategy  
 
Adoptive transfer of 10x106 activated OT-1 CTLs into RIP-mOVA mice induced 
antigen-specific pancreas and renal inflammation  
 
Diabetes development in RIP-mOVA mice 
The adoptive transfer of high amounts of activated OT-1 CD8+ CTLs into RIP-mOVA mice 
should lead to pancreas and kidney infiltration (5). After i.v. injection of 10x106 of in vitro 
activated effector OT-1 CTLs into RIP-mOVA (Tg/+), non-transgenic littermate control (non-
Tg) or B6 mice, 60% of the RIP-mOVA mice developed glucosuria on day 3. At day 5, 80% 
of the RIP-mOVA mice showed high levels of glucosuria (55 mmol/l). Non-transgenic 
littermate controls or B6 mice did not develop glucosuria until the end of the experiment on 















































Figure 2: The onset of glucosuria in RIP-mOVA mice, non-transgenic 
littermates and C57BL/6 mice after adoptive transfer of 10x106 activated OT-1 
CD8+ T cells. The figure depicts a summarization of all the experiments in which 
mice were transferred with 10x106 activated OT-1 CD8+ T cells. RIP-mOVA (Tg/+) 
mice (n=16); non-transgenic (non-Tg) littermates (n=9); C57BL/6 mice (n=14). 
 
 
The overview staining with H&E on the pancreas sections of glucosuric RIP-mOVA mice 
revealed a complete destruction of the architecture compared to the control animals (Fig. 3).  
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Figure 3: H&E staining of pancreas 
sections of C57BL/6 and RIP-mOVA 
mice 5 days after adoptive transfer 
of 10x106 activated OT-1 CD8+ T 







Induction of kidney inflammation and infiltration in RIP-mOVA mice  
Then the assessment of kidney infiltration and inflammation after the CTL transfer was 
performed on sections of cryopreserved kidneys. Focal accumulation of CD8+ positive T cells 
was detected around many tubular epithelial cells (Fig. 4B). The kidney sections of control B6 
mice showed only few positive CD8+ T cells and no cluster of these cells around the tubules 
was observed (Fig. 4A), suggesting that the positively stained CD8+ T cells in the kidneys of 
RIP-mOVA mice were the transferred OT-1 CD8+ T cells. There was a slight increase in the 
number of CD4+ T cells in the kidneys of RIP-mOVA mice compared to the B6 controls (Fig. 
4C and D). Interestingly, MHC class II expression was strongly induced on TECs in RIP-
mOVA mice (Fig. 4F) but not on tubules of B6 mice (Fig. 4E). MHC class II positive 
interstitial cells, most likely DC (9), were found in both groups. Similarly, strong staining of 
PD-L1 was detected on the tubular cells of RIP-mOVA mice (Fig. 4H) but not on the tubules 
of control B6 mice (Fig. 4G). 
 
 
Figure 4: Immunofluorescence staining of kidney sections from C57BL/6 mice (A, C, E, G) 
and RIP-mOVA mice (B, D, F, H) 5 days after injection of 10x106 activated OT-1 CD8+ T 
cells. Sections of cryopreserved kidneys were stained with anti-mouse antibodies against (A, B) 
CD8+, (C, D) CD4+, (E, F) MHC class II and (G, H) PD-L1.Magnification 40x.  
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Taken together, the adoptive transfer of 10x106 activated OT-1 CD8+ T cells into RIP-mOVA 
mice induced a focal accumulation of CD8+ T cells around tubules accompanied by an 
induction of MHC class II and PD-L1 expression on tubular epithelial cells. 
 
To test the hypothesis that PD-L1 on parenchymal tissue, (e.g. the kidney and the pancreas) 
has a protective role, the next experiments were aimed to inhibit the renal epithelial PD-1/PD-
L1 pathway in vivo. This was performed by administration of specific anti- PD-L1 
monoclonal Ab (αPD-L1) or PBS after transferring 10x106 OT-1 CTLs into RIP-mOVA or 
B6 mice, respectively. Both αPD-L1 or PBS treatment groups developed glucosuria on day 3. 
At the end of the experiment (day 5), 80% of the RIP-mOVA mice treated with αPD-L1, and 
60% of the RIP-mOVA mice injected with PBS had displayed glucosuria (difference n.s., Fig. 
5). 
 














































Figure 5: Development of glucosuria in RIP-mOVA and C57BL/6 mice treated 
either with αPD-L1 or PBS after adoptive transfer of 10x106 activated OT-1 
CD8+ T cells. RIP-mOVA mice + αPD-L1 (n=5); RIP-mOVA mice + PBS (n=5); 
C57BL/6 mice + αPD-L1 (n=3); C57BL/6 mice + PBS (n=3). 
 
 
The measurement of blood glucose was started in the afternoon of day 3 when the onset of 
glucosuria had been detected. All of the RIP-mOVA mice, except one treated with αPD-L1, 
exhibited elevated blood glucose levels (> 8 mmol/l) in the afternoon at day 3. All of the RIP-
mOVA mice were treated with insulin Actrapid®. Since this drug has only a half life of 3-4 h, 
the blood glucose levels were raised the next morning and the mice were treated with insulin 
twice on day 4 when blood glucose levels were > 8 mmol/l. There was no significant 
difference in the levels of blood glucose between both RIP-mOVA groups over the 
experimental period after the onset of glycaemia (Fig. 6). B6 mice treated either with αPD-L1 
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or PBS after the CTL transfer did not develop glucosuria and glycemia until the end of the 
experiment (Fig.5 and 6). 
 
Figure 6: Blood glucose levels on day 
3-5 after adoptive transfer of 10x106 
OT-1 CD8+ T cells. The values on day 
4 represent the mean of the morning and 
the afternoon measurements whereas the 
levels on day 3 were determined in the 
afternoon and on day 5 in the morning 
before termination of the experiment. 
The blood glucose in C57BL/6 mice 
was measured only on day 4 and 5. RIP-
mOVA mice + αPD-L1 (n=5); RIP-
mOVA mice + PBS (n=5); C57BL/6 
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The tubulointerstitial infiltration in the 4 different groups was assessed by overview staining 
with PAS on sections from formalin-fixed kidneys. Tubulointerstitial infiltration and focal 
accumulation of cells around tubules was detected in kidneys of both groups of RIP-mOVA 
mice with or without αPD-L1 treatment (Fig. 7C and D). However, the PAS staining revealed 
no obvious difference in the level/rate of infiltration between RIP-mOVA mice treated with 
αPD-L1 or PBS. The kidneys of B6 mice were not infiltrated (Fig. 7A and B). 
 
Figure 7: Representative pictures of the 
PAS staining of sections from formalin-
fixed kidneys at day 5 after transfer of 
10x106 activated OT-1 CD8+ T cells into 
RIP-mOVA and C57BL/6 mice. (A) 
C57BL/6 + αPD-L1 (n=3); (B) C57BL/6 mice 
+ PBS (n=3); (C) RIP-mOVA mice + αPD-L1 









CD3 staining (as a marker for T cells) was performed to better quantify the infiltration. The 
kidneys of RIP-mOVA mice that were treated with αPD-L1 showed a significant higher 
number of infiltrated CD3+ cells compared to the kidneys of B6 mice (Fig. 8) but different 
levels of infiltration were not detectable between kidneys of RIP-mOVA mice either treated 
with αPD-L1 or PBS. One mouse of the RIP-mOVA mice treated with αPD-L1 and two mice 
of the RIP-mOVA mice injected with PBS had low or no infiltration of CD3+ cells in the 
kidneys after adoptive transfer. These were the same mice that had not developed glycemia 








































Figure 8: (A-D) Representative pictures of the CD3 staining of sections from formalin-fixed 
kidneys at day 5 after transfer of 10x106 activated OT-1 CD8+ T cells into RIP-mOVA and 
C57BL/6 mice. (E) Quantification of the CD3 staining. (A) C57BL/6 + αPD-L1 (n=3); (B) 
C57BL/6 mice + PBS (n=3); (C) RIP-mOVA mice + αPD-L1 (n=5); RIP-mOVA mice + PBS (n=5). 
Magnification 25x. (E) * < 0.05 analyzed with Mann-Whitney U-test. 
 
 
In summary, treatment of RIP-mOVA mice with αPD-L1 antibody or PBS after adoptive 
transfer of 10x106 OT-1 CD8+ T cells revealed no significant differences in the onset/severity 
of diabetes and the level of tubulointerstitial infiltration.  
 
Retrieval of OVA-specific CD8+ T cells in RIP-mOVA and B6 mice 5 days after transfer 
At day 5 after adoptive transfer, the presence of OT-1 CD8+ T cells in splenocytes of RIP-
mOVA or B6 mice was determined using pentamer staining and was compared with 
splenocytes of OT-1 mice. As a positive control, 95% of the CD8+ T cells of OT-1 mice were 
specific for OVA257-264 peptide (Fig. 9A). OVA-peptide specific CD8+ T cells could not be 
detected in naïve RIP-mOVA and B6 mice (data not shown). B6 mice had still 27-51% 
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specific CD8+ T cells in the spleen after adoptive transfer (Fig. 9C and D). In contrast, RIP-
mOVA mice, regardless of their treatment, exhibited a significant lower population of 
OVA257-264 peptide CD8+ T cells (7-16%). There was no significant difference in the OVA-
peptide specific CD8+ T cell population between the RIP-mOVA mice treated with αPD-L1 
or PBS (Fig. 9D). The significant lower number of specific CD8+ T cells in the spleen of RIP-
mOVA compared to the B6 mice suggested that the transferred CD8+ T cells might home to 





































































Figure 9: FACS staining of OVA257-264 peptide-specific CD8+ T cells in the spleens of 
RIP-mOVA and C57BL/6 mice at day 5 after transfer of 10x106 activated OT-1 CD8+ T 
cells. 1x106 splenocytes were stained with anti-mouse CD8-FITC and Pro5 MHC Pentamer-
PE against SIINFEKL to test the specificity of CD8+ T cells. Representative FACS blots of 
the staining of splenocytes from (A) naïve OT-1 mice as a positive control; (B) RIP-mOVA 
mice after adoptive transfer and (C) C57BL/6 mice after adoptive transfer. (D) Comparison of 
the relative number of OVA-specific CD8+ T cells between RIP-mOVA and C57BL/6 mice 
either treated with αPD-L1 or PBS. RIP-mOVA mice + αPD-L1 (n=5); RIP-mOVA mice + 
PBS (n=5); C57BL/6 mice + αPD-L1 (n=3); C57BL/6 mice + PBS (n=3). * < 0.05 analyzed 
with Mann-Whitney U-test. 
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In addition, these results suggested that the injected cells could still be found in the circulation 
of these mice and had not been depleted on day 5 after adoptive transfer. 
 
 
Adoptive transfer of a lower amount (2.5x106) of activated OT-1 CD8+ T cells 
It might be that the number of 10x106 of activated OT-1 CTL was too high to distinguish 
differences in the onset of diabetes and kidney infiltration in RIP-mOVA mice after the 
administration of αPD-L1. Consequently, a lower number of activated OT-1 CD8+ T cells was 
transferred. 
 
After the transfer of 2.5x106 activated OT-1 CTLs RIP-mOVA mice were also treated with 
αPD-L1 or isotype control (rat IgG) on day 1 and 3. Insulin Levemir® Penfill® 3 was injected 
into the mice when blood glucose levels were > 8 mmol/l. 
 
As shown in Figure 10, 40% of the RIP-mOVA mice treated with αPD-L1 developed diabetes 
on day 3 after adoptive transfer of 2.5x106 activated OT-1 CD8+ T cells. At day 5, all of the 
mice of this group displayed glycemia (Fig. 10A). 30% of the RIP-mOVA mice injected with 
the isotype control developed diabetes on day 4 after the CTL transfer and all of the mice 
were glycemic on day 6 when the experiment was terminated. Although, the levels of blood 
glucose measured on day 3 and 4 in RIP-mOVA mice with αPD-L1 treatment seemed to be 
higher than in the RIP-mOVA isotype group, they did not differ statistically and this 
difference was diminished after day 5 when almost all mice in both groups became diabetic. 
 
Tubulointerstitial infiltration was hardly detectable after adoptive transfer of 2.5x106 activated 
OT-1 CD8+ T cells. Only a few cells in the interstitium could be found. There was no obvious 
difference in the level of infiltration between RIP-mOVA mice treated with αPD-L1 or PBS 
(data not shown). 
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Figure 10: Diabetes development in RIP-mOVA mice treated either with αPD-
L1 or isotype after transfer of 2.5x106 activated OT-1 CD8+ T cells. (A) Onset of 
glycemia, p=0.0529 (n.s.) (B) Blood glucose levels on day 3 to 6 after adoptive 
transfer. The values on day 4 and 5 represent the mean of the morning and the 
afternoon measurements whereas the levels on day 3 were determined in the 
afternoon and on day 6 in the morning before termination of the experiment. RIP-
mOVA + αPD-L1 (n=5), RIP-mOVA mice + isotype (n=6). 
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4.4.2. Immunization strategy  
Summary of the immunization strategies 
Transgenic and non-transgenic RIP-mOVA were immunized with 100 µg OVA protein and 
50 µg OVA257-264 peptide in incomplete Freud’s adjuvant. Different protocols regarding the 
amount of immunizations and the duration of the experiment were tested. A summary of the 
performed immunization experiments including the number of immunizations, animals and 
the day of termination of the experiment are depicted in Table 1. 
 
Table 1: Summary of the immunization experiments 
RIP-mOVA n x immunization 






non-Tg 1x 6 4 0/4 
non-Tg 2x 14 5 0/5 
non-Tg 2x 20 3 0/3 
non-Tg 3x 30 3 0/3 
Tg/+ 1x 6 5 2/5 
Tg/+ 2x 14 4 4/4 
Tg/+ 2x 20 2 2/2 
Tg/+ 3x 30 3 3/3 
 
non-transgenic (non-Tg), transgenic (Tg/+). Tubular inflammation was determined by the 
observation of MHC class II induction on TECs. 
 
One immunization with OVA antigens induced tubular inflammation which was determined 
by MHC class upregulation on TECs (10, 11) in two out of five RIP-mOVA mice (Tg/+). 
Consequently, mice were repeatedly immunized in the following experiments and different 
time points after the second immunization were investigated. All of the immunized RIP-
mOVA mice showed upregulation of MHC class II expression on TECs after the second and 
third immunization. None of the non-transgenic mice or B6 mice (data not shown) developed 
tubular inflammation.  
 
Development of glucosuria 
In total only 4 animals of all immunized RIP-mOVA mice developed glucosuria (levels were 
between 5.5-17mmol/l). Glucosuria was observed in two animals after the second 
immunization on day 14 and in two mice on day 20. Mice that were immunized thrice did not 
develop glucosuria (data not shown). 
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Induction of kidney inflammation 
A mild infiltration of CD4+ and CD8+ T cell into the kidneys of RIP-mOVA mice was 
observed after two (Fig. 11B, D) and three times of immunization. The T cells were overall 
distributed and accumulation of T cells around tubules was only found sporadically. Non-
transgenic controls or B6 mice only showed single cells being positive for CD4 and CD8 
staining (Fig. 11A and C). MHC class II expression was strongly induced on many TECs in 
RIP-mOVA mice after immunization (Fig. 11F) whereas tubules of non-transgenic or B6 
mice only showed interstitial MHC class II expression (Fig. 11E). Tubules as well as 
glomeruli and vessels showed a strong staining of PD-L1 (Fig. 11H) in RIP-mOVA mice 
whereas kidneys of non-transgenic and B6 mice were negative for the expression of PD-L1 
(Fig. 11G).  
 
 
Figure 11: Immunofluorescence staining of kidney sections from non-transgenic RIP-
mOVA/B6 mice (A, C, E, G) and RIP-mOVA mice (Tg/+) (B, D, F, H) which were 
immunized twice, day 14. The pictures are as well representative for mice immunized twice, day 
20 and thrice, day 30. Sections of cryopreserved kidneys were stained with anti-mouse antibodies 
against (A, B) CD8+, (C, D) CD4+, (E, F) MHC class II and (G, H) PD-L1. Magnification 40x. 
 
 
Immunization with “self-antigens” did not induce tolerance in RIP-mOVA mice 
In vivo development of OVA-specific T cells after immunization was determined by ex vivo 
stimulation of CD4+ and CD8+ T cells with OVA protein and OVA257-264 peptide, 
respectively. CD8+ T cells isolated from immunized transgenic, non-transgenic RIP-mOVA 
and B6 mice produced IFN-γ after exposure with splenocytes loaded with OVA257-264 peptide 
whereas CD8+ T cells pulsed with splenocytes not loaded with peptide did not secrete IFN-γ 
(Fig. 12A). An OVA-protein specific proliferation of CD4+ T cells derived from immunized 
mice was as well observed (Fig. 12B). T cells isolated from non-immunized (naïve) RIP-













































Figure 12: Representative graphs of (A) IFN-γ production of OVA-peptide specific 
CD8+ T cells and (B) OVA-protein specific CD4+ T cell proliferation. T cells were 
isolated from spleens and LNs of immunized RIP-mOVA and non-transgenic controls. (A) 
CD8+ T cells were stimulated with splenocytes loaded with (+) or without (w/o) OVA257-264 
peptide for 48 h. (B) CD4+ T cells were stimulated with different concentrations of OVA-
protein as indicated for 72 h. ConA was used as a positive control for CD4+ T cell 
proliferation. The graph shows the T cell responses of one animal/group after two times 
immunization, day 14 but the pattern and the antigen-dependent response are representative 
for transgenic, non-transgenic RIP-mOVA and B6 mice which were immunized once, twice 
and thrice.  
 
 
One immunization with OVA-antigens was efficient to generate antigen-specific T cells in 
transgenic and non-transgenic RIP-mOVA and B6 mice (data not shown). The antigen-
dependent ex vivo T cell response of immunized RIP-mOVA mice indicated that these RIP-
mOVA mice, although they express OVA-antigens as self antigens, developed antigen-






Two different approaches were used to investigate the expression and the role of renal 
epithelial PD-L1 in vivo. The first one was to use the established (5) protocol for adoptive 
transfer of activated OT-1 CD8+ T cells into RIP-mOVA mice and the second one was to 
immunize RIP-mOVA mice with self-antigens to induce a pathophysiological autoimmune 
response in the kidney.  
 
RIP-mOVA mice developed diabetes after the transfer of activated OT-1 CD8+ T cells, 
indicating that the method published by Kurts et al. is reproducible and reliable (5). The 
incidence of 70-100% diabetes development in RIP-mOVA mice after the transfer of high and 
low amounts of OT-1 CD8+ T cells suggested that some of the animals might have a different 
expression of mOVA. Another possibility might be that the termination of the experiment on 
day 5 after the transfer of high amounts was too early. Mice that did not suffer from diabetes 
also did not demonstrate kidney infiltration. Consequently, only mice developing diabetes 
should take into account for the investigation of kidney pathology/inflammation after transfer 
of OT-1 CD8+ T cells in the future experiments. 
 
The transfer of high amounts of self-reactive OT-1 CD8+ T cells into RIP-mOVA mice 
caused a rapid accumulation of CD8+ T cells around kidney tubules certainly OVA-
expressing TECs as described (5). Furthermore, TECs surrounded by CD8+ T cells showed an 
induction of MHC class II and PD-L1 expression suggesting a local inflammatory 
environment. For instance, IFN-γ secretion by infiltrating CD8+ T cells could be responsible 
for the induction of MHC class II and PD-L1 on TECs. This needs to be confirmed in future 
experiments investigating the intrarenal expression of cytokines, e.g. IFN-γ or TNF-α that are 
known to upregulate these molecules on TECs. The immunization of RIP-mOVA mice with 
“self”-antigens, i.e. OVA peptide and protein, caused only mild T cell infiltration into the 
kidneys but induced as well a marked upregulation of MHC class II and PD-L1. Interestingly, 
PD-L1 expression was not only found on TECs but as well on glomeruli and vessels of the 
kidney. One might speculate that the immunization caused a systemic inflammatory cytokine 
response leading to a broad upregulation of MHC class II and PD-L1 in kidneys in contrast to 
the CTL transfer. 
Although OVA is a self-antigen of RIP-mOVA mice, the immunization with OVA peptide 
and protein primed OVA-specific CD4+ and CD8+ T cells in vivo, as assessed by ex vivo 
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antigen-specific T cell responses. Consequently, RIP-mOVA mice were not tolerant and 
developed auto-reactive T cells after immunization with “self”-antigens. Nevertheless, only 
four mice had glucosuria, suggesting infiltration and destruction of the pancreas by in vivo 
primed auto-reactive T cells. The same animals exhibited strong MHC class II and PD-L1 
expression in the kidney. However, even repeated immunizations with OVA-antigens were 
not powerful enough to induce moderate T cell infiltration into kidneys and probably the 
pancreas as well. 
 
The induction of PD-L1 on TECs in RIP-mOVA mice after the transfer of OVA-specific CTL 
and after the immunization with OVA antigens suggested an involvement of the PD-1/PD-L1 
pathway in autoimmune pancreas and kidney responses. However, the blockade of this 
pathway by monoclonal antibodies against PD-L1 on day one and three after the transfer of 
high amounts of activated OT-1 CTL did not change the disease development such as the 
onset of diabetes and kidney infiltration. This might be due to the fact that the number of 
10x106 activated CD8+ T cells was too high to distinguish differences in the outcome. 
Consequently, a lower amount of activated OT-1 CD8+ T cells (2x106) was transferred. 
Although the transfer of lower numbers of CTLs did efficiently induce diabetes, no significant 
kidney infiltration was detected which is in agreement with the literature (5). 
 
Blockade of PD-L1 with the same clone of Ab caused diabetes in RIP-mOVA mice after 
transfer of 5x105 naïve OT-1 CTL whereas this low amount of OVA-specific CD8+ T cells 
alone was not sufficient to induce diabetes (12). The inhibition of PD-L1 after the transfer of 
the lower amount of activated OT-1 CTL did not change the onset of diabetes significantly, 
but a tendency towards an earlier onset was seen in RIP-mOVA mice treated with αPD-L1. 
This suggests that the number of 2.5x106 CTL was still too high to observe differences in the 
diabetes outcome. However, this amount was too low to induce tubulointerstitial infiltration in 
our experimental setup, and the treatment with αPD-L1 was not sufficient to trigger kidney 
infiltration. This result leaves open questions whether the injected antibody was able to reach 
the kidney and to block renal tubular epithelial expression. In addition, the focal PD-L1 
expression on certain tubules induced by the CTL transfer method may not have been strong 
enough to alter the total disease development and therefore inhibition of PD-L1 by αPD-L1 
mAbs was not sufficient to enhance kidney infiltration.  
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Another possibility to interrupt the PD-1/PD-L1 pathway in vivo is to transfer activated OT-1 
CTLs that lack the receptor PD-1. RIP-mOVA mice developed diabetes after transfer of PD-1-
/- OT-1 CTLs whereas transfer of wt OT-1 CTLs was not sufficient to induce diabetes (13). 
This approach might work as well to enhance kidney infiltration and could be one of the 
future experiments. 
 
Anti PD-L1 treatment in the immunized RIP-mOVA mice might be a more suitable approach, 
since 1) the immunization protocol induced a broad expression of PD-L1 in kidneys and this 
might be more powerful to modulate T cell infiltration. Anti-PD-L1 Ab administration will 
clarify whether high expression of PD-L1 in kidneys limits infiltration of T cells and is 
protective, or if there is the necessity to develop a stronger immunization protocol to break the 
tolerance. 2). The first immunization experiments indicate that there is less influence on the 
occurrence of diabetes. 
 
Nevertheless, a recent study has shown that the PD-1/PD-L pathway limited autoimmune-
mediated kidney diseases. The expression of PD-L1, PD-L2 and PD-1 was increased in 
kidneys during nephrotoxic serum nephritis (NSN). In mice lacking PD-L1 (PD-L1-/-), PD-L2 
(PD-L2-/-) or both molecules (PD-L1/L2-/-) kidney pathology, loss of renal function and 
intrarenal leukocyte infiltration were enhanced compared to wild type mice during NSN. 
Specifically, activated CD8+ T cells were increased in diseased kidneys of PD-L1-/- mice 
whereas the absence of PD-L2 enhanced infiltration of macrophages. However, this study has 
demonstrated that PD-L1 expression on kidney parenchymal cells was not responsible for 
limiting leukocyte infiltration but rather PD-L1 on hematopoietic cells (14).  
 
In conclusion, the transfer of high amounts of activated OVA-specific CD8+ CTL and the 
immunization with OVA antigens represent two different strategies to induce kidney 
inflammation and mild to moderate kidney infiltration in RIP-mOVA mice. Both 
experimental approaches are useful tools to investigate the expression of molecules including 
PD-L1 in autoimmune kidneys. The CTL transfer protocol is suitable to study acute 
tubulointerstitial nephritis whereas the immunization strategy may be used to investigate 
chronic autoimmune tubulointerstitial inflammation and infiltration. However, the pancreas 
seems to be more prone to autoimmune responses in this model than the kidney. Therefore, 
tubulointerstitial nephritis will always be accompanied by severe islet cell injury and the 
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Renal proximal tubular epithelial cells (TECs) are targeted by infiltrating T cells during renal 
allograft rejection. The co-inhibitory molecules PD-L1 and PD-L2 are ligands of Programmed 
Death-1 (PD-1) and may protect TECs from T cell-mediated injury. In this study, we 
investigated the functional role of the PD-1/PD-L pathways in human renal allografts. In 
cultured human primary TECs the treatment with IFN-β and IFN-γ revealed a dose-dependent 
and synergistic increase of PD-L1 and PD-L2 expression. Their functional role was analyzed 
by human allogeneic T cell responses to TECs in vitro. Blockade of surface PD-L1, but not 
PD-L2, on TECs pre-treated with IFNs resulted in a significantly increased CD4+ T cell 
proliferation and cytokine production by CD4+ and CD8+ T cells. PD-L1, PD-L2 and PD-1 
mRNA and protein expression were upregulated in biopsies of patients with renal allograft 
rejection compared to pretransplant biopsies. PD-L1 induction was significantly associated 
with acute vascular rejection. In conclusion, our study suggests an inhibitory effect of the 
renal epithelial PD-1/PD-L1 pathway on alloreactive T cell responses. The upregulation of 
PD-L1 on TECs in patients with acute allograft rejection may reduce T cell-mediated injury. 
75
Introduction 
Acute renal allograft rejection remains a major obstacle for long-term allograft survival as it 
predisposes to chronic allograft injury with a progressive decline of renal function. Renal 
proximal tubular epithelial cells (TECs) are the main target of infiltrating alloreactive CD4+ 
and CD8+ T cells causing tubulointerstitial injury (1). The local inflammation induces MHC 
class I and class II expression on donor TECs, allowing recognition of allogeneic 
MHC/peptide complexes by recipient T cells (signal 1) (2). An additional signal 2 required 
for full T cell activation is provided by the binding of co-stimulatory molecules on APCs to 
their receptors on T cells (e.g. B7/CD28). In contrast a number of known co-inhibitory 
molecules downregulate T cell responses. PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, 
CD273) are ligands for the Programmed-death 1 (PD-1, CD279) molecule which is induced 
on activated T and B cells. PD-L1 and PD-L2 are expressed on hematopoietic cells and 
parenchymal tissues such as heart, lung, liver, placenta and kidney (3, 4). Binding of PD-L1 
or PD-L2 to PD-1 inhibits lymphocyte activation (3, 4).  
 The expression profile of co-stimulatory and co-inhibitory molecules on TECs is 
limited (5). While TECs do not express the typical co-stimulatory molecules B7.1 and B7.2 
(6, 7), they express CD40 as a co-stimulatory molecule. PD-L1 is the most prominent co-
inhibitory molecule on TECs. We and others previously observed that PD-L1 is strongly 
expressed in rejected murine kidney transplants, and that PD-L1 is markedly upregulated on 
cultured murine TECs after treatment with inflammatory cytokines (8, 9). Furthermore, high 
PD-L1 expression by murine TECs impairs antigen-specific CD4+ and CD8+ T cell responses 
(5, 8, 10). Several other studies demonstrated that the PD-1/PD-L1 pathway directly 
attenuates allograft rejection in experimental models of heart, skin and pancreas 
transplantation (11-13). Furthermore, PD-1 played a crucial role for the induction of CD8+ T 
cell tolerance in an allogeneic mixed chimerism model (14). 
 The functional role of PD-1/PD-L pathways in human kidney allograft rejection is 
unknown. Thus, the goal of the present study was to investigate the function of PD-L1 and 
PD-L2 on human TECs in modulating alloreactive CD4+ and CD8+ T cell responses. 
Furthermore, expression of PD-L1, PD-L2 and PD-1 was evaluated in biopsies of kidney 




Materials and Methods 
General reagents 
Cell culture reagents were obtained from Invitrogen (Gaithersburg, MD) and Sigma (St. 
Louis, MO). Human cytokines were purchased from R&D Systems (Oxford, UK).  
 
Human cell lines and primary TEC cultures 
The human renal TEC line HK-2 was cultured in K1 medium (15). Primary cultures of human 
TECs were generated from healthy parts of tumor nephrectomies from three patients (patient 
1-3). Briefly, small fragments of cortical tissue were digested twice with type II collagenase 
(1 mg/ml in HBSS) (Invitrogen) for 90 min at 37°C. The cell suspension was passed through 
40 μm sieves, washed and seeded on collagen-coated cell culture plates in K1 medium 
containing human EGF (5 ng/ml). Next day, after washing with HBSS; fresh K1 medium was 
added to allow primary TECs growing at 37°C in 5% CO2 until confluence (5-7 days). 
Epithelial cell origin confirmed by positive cytokeratin staining was more than 95%. In 
functional assays, the 2nd passage of TECs with positive cytokeratin expression was used as 
APCs, which demonstrated a similar pattern of surface molecule expression and antigen-
presentation capacity compared to the original primary TECs.  
  
Flow cytometric analysis 
Human TECs were harvested by trypsinization, washed and stained with mAb (all mouse 
anti-human) against PD-L1 (clone MIH1), PD-L2 (clone MIH18), HLA-ABC (clone W6/32) 
and HLA-DR (clone LN3). mAbs were purchased from eBioscience (San Diego, CA). Cells 
were analyzed using a FACSCantoII flow cytometer (BD Biosciences) and FlowJo software 
Version 7 (Tree Star, OR, USA).  
 
Isolation and activation of human CD4+ and CD8+ T cells in vitro  
Human PBMCs were isolated from heparinized whole blood of healthy volunteers (n=5) and 
of patient 2 (who provided the tissue for isolating TECs = P2 TEC) using Lymphoprep™ 
(AXIS-SHIELD PoC AS, Oslo, Norway) according to the manufacturer’s protocol. PBMCs 
were washed with PBS three times followed by CD4+ and CD8+ T cell isolation with human 
CD8 and CD4 MACS microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), 
respectively. CD4+ and CD8+ T cells of healthy volunteers were then pre-activated either with 
PHA or allogeneic PBMCs to upregulate PD-1 expression on T cell surfaces:  
1. PHA activation: 
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Isolated CD4+ and CD8+ T cells of healthy donors were adjusted to 2x106cells/ml in IMDM 
medium supplemented with 10% FCS, seeded into 24-well-pates and incubated at 37°C, 5% 
CO2. Activation of T cells was performed by adding 2 μg/ml of PHA for 5 days. 
2. Allogeneic and autologous activation:  
The T cell depleted fraction of PBMCs (CD4-CD8-PBMCs) of patient 2 was irradiated with 
30 Gy and then co-cultured with purified CD4+ or CD8+ T cells of one healthy donor at a ratio 
of 2:1 (T cells:PBMCs) for 3 days in the presence of human IL-2 (5 ng/ml). As a control, 
CD4+ and CD8+ T cells of the same healthy donor were stimulated with their own CD4-CD8- 
PBMCs (autologous stimulation) under the same conditions. 
 
Alloreactive CD4+ T cell proliferation induced by TECs 
Human primary TECs were pre-treated with human IFN-β and IFN-γ (100 U/ml each) for 2 
days. Cells were then harvested by trypsinization, washed and irradiated with 60 Gy. 
Irradiation did not influence the expression of PD-L1 and PD-L2 (data not shown). After 
washing, TECs were resuspended in IMDM and seeded in 96-well plates. TECs were pre-
incubated with the relevant mAbs (PD-L1, PD-L2 or isotype control) for 1 h at 37°C prior to 
addition of pre-activated CD4+ T cells at the indicated T cell/TEC ratios. T cell proliferation 
was determined after 72 h of co-incubation by using the non-radioactive colorimetric 
CellTiter 96® AQueous One Solution Cell Proliferation Assay kit (Promega) according to the 
manufacturer’s protocol. Results were presented as the value of the OD at 490 nm after 
subtraction of the OD values from medium alone and calculated as follows: ODexperimental – 
ODTEC alone – OD T cell alone.  
 
Alloreactive CD8+ T cell cytokine production stimulated by TECs 
Human primary TECs were pre-treated with IFN-β and IFN-γ for 2 days, harvested and pre-
incubated with the relevant mAbs or isotype control for 1 h, and then seeded in 96-well plates. 
Pre-activated human CD8+ T cells were added at a responder/stimulator ratio of 30:1 (3x105 
CD8+ T cells to 1x104 TECs) for 48 h.  
 
Measurement of cytokines  
Cytokine production was determined in the coculture supernatants after 48 h (CD8+ T cell 
response) and 72 h (CD4+ T cell response), respectively, either by human specific ELISA kits 
for IFN-γ or IL-2 (eBioscience, San Diego, USA) or by the BD™ CBA Flex Sets (BD 
Biosciences, San Jose, USA) according to the manufacturer’s protocols.  
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Quantitative real-time PCR of renal biopsies 
Human renal biopsy specimens were procured in an international multicenter study, the 
European Renal cDNA Bank-Kroener-Fresenius Biopsy Bank (ERCB-KFB). Biopsies were 
obtained from patients after informed consent and with approval of the local ethics 
committees. Clinical characteristics of all patients are shown in Table I. Tubulointerstitial 
tissue was prepared and analyzed by real-time RT-PCR as reported earlier (16). Pre-
developed TaqMan reagents were used for human PD-L1 (CD274) [NM_014143.2], PD-L2 
(CD273, PDCD1LG2) [NM_025239.2], and PD-1 (CD279, PDCD1,) [NM_005018.1] as well 
as the housekeeper genes (GAPDH and 18SrRNA; Applied Biosystems). The mRNA 
expression was analyzed by standard curve quantification. Normalization to both housekeeper 
genes gave comparable results; data based on 18S rRNA are shown.  
 
Immunohistochemistry 
Immunohistochemistry was performed as previously described (17). The biopsies were 
archival materials collected retrospectively at the University of Vienna (2006-2008). In brief, 
sections were dewaxed in xylene, rehydrated in a series of graded ethanols, incubated in 3% 
hydrogen peroxide (to block endogenous peroxidases). To block endogenous biotin the 
Avidin/Biotin blocking Kit (Vector, Burlingame, CA) was used. Ag retrieval was performed 
in an autoclave oven in Ag retrieval solution. Incubation with the primary Ab was performed 
for 1 h or overnight. Incubation with biotinylated secondary Ab was for 30 min, followed by 
the ABC reagent. For PD-1, two consecutive secondary Abs were used to enhance the signal. 
3’3’Diaminobenzidine (DAB, Sigma, Taufkirchen, Germany) with metal enhancement 
(resulting in a black color product) served as detection system. The rabbit polyclonal Ab 
against PD-L1 (ab41890, Abcam, Cambridge, UK) was used in a dilution of 0.5 µg/ml (1:400 
in 10 % non-fat dry milk). The Ab was raised against a peptide corresponding to amino-acids 
144-291 of human PD-L1. The peptide was used to block the signal via pre-incubation of the 
Ab as additional control. Furthermore non-immune rabbit serum was used as a negative 
control. The mAb mouse anti-human PD-1 (clone MIH4, Natutec, Frankfurt am Main, 




All in vitro cell experiments were performed in triplicates and were repeated at least twice. 
Data are expressed as mean ± SD. The unpaired Student’s t test was used to analyze all data 
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of the in vitro experiments. Mann Whitney test was used to perform statistical analysis of PD-
L1, PD-L2 and PD-1 mRNA expression in human biopsies. Additional Bonferroni correction 
was applied to assess for multiple testing for the mRNA levels. Pearson’s correlation was 
done to correlate mRNA expressions to the clinical characteristics. Significance was accepted 




PD-L1 and PD-L2 surface expression on human renal TECs upon IFN-β and IFN-γ treatment 
in vitro 
To explore the functional role of PD-L1 and PD-L2 on human TECs, we first studied the 
expression pattern on cultured TECs. TECs were stimulated with human IFN-β and IFN-γ for 
48 h. PD-L1 and PD-L2 were constitutively expressed on TECs (Fig. 1A). Treatment with 
either IFN-β or IFN-γ was able to further upregulate the expression of both PD-L1 and PD-L2 
in a dose dependent manner (Fig. 1A). Furthermore, stimulation of TECs with both INFs 
revealed a synergistic effect (Fig. 1B). We performed these experiments with primary TECs 
(n=3) and HK-2 cells and obtained similar results (data not shown). 
 Stimulation with IFN-β and IFN-γ also strongly upregulated constitutive MHC class I 
expression (Fig 1C). MHC class II molecules were not constitutively expressed on TECs (Fig. 
1C), but stimulation with IFN-γ led to a marked increase. IFN-β had no effect.  
 
PD-L1 on TECs inhibited proliferation and cytokine production of CD4+ T cells  
In these experiments, alloreactive CD4+ T cell proliferation was performed by incubating 
PHA-activated human CD4+ T cells with IFN-pretreated human TECs. Anti-PD-L1 and -PD-
L2 mAbs or isotype controls were included to examine the function of renal epithelial PD-L1 
and PD-L2. As shown in Fig. 2A, compared to the anti-CD3 mAb-induced CD4+ T cell 
proliferation, TECs generated from nephrectomized kidneys of 2 patients (P1 and P2 TEC) 
induced a very weak T cell proliferation. Importantly, double blockade of PD-L1 and PD-L2 
on both P1 and P2 TECs significantly increased the CD4+ T cell proliferation and cytokine 
production (Fig. 2A and 2C). To further define whether the enhancement of T cell 
proliferation was mediated via the blockade of PD-L1, PD-L2 or both, single blockade was 
performed. Interestingly, inhibition of PD-L1 alone was able to augment CD4+ T cell 
proliferation, which was comparable to the responses obtained with double blockade. In 
contrast, PD-L2 blockade was not effective (Fig. 2B). 
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 The cytokine profile in the supernatants of CD4+ T cell/TECs co-cultures was 
investigated, including IL-2, IL-4, IL-10, IFN-γ and TNF-α. Similar to the T cell proliferation, 
TECs stimulated negligible IFN-γ production comparable to the baseline level of IFN-γ 
production by CD4+ T cells alone (Fig. 2C). Inhibition of PD-L1 on TECs significantly 
increased the IFN-γ production up to 5-10-fold. Again, the same magnitude of IFN-γ secretion 
was seen when both PD-L1 and PD-L2 on TECs were blocked, whereas inhibition of PD-L2 
alone had no effect. TNF-α secretion by CD4+ T cells was also observed only after PD-L1, 
but not PD-L2 blockade (data not shown). Although proliferation of CD4+ T cells after 
blockade of PD-L1 on TECs could be measured, IL-2 production was not detectable in the 
supernatants of CD4+ T cell/TECs co-culture after 72 h (data not shown). In addition, CD4+ T 
cells did not produce IL-4 or IL-10 after stimulation with TECs under these experimental 
conditions (data not shown).  
 
PD-L1 on TECs inhibited cytokine production of CD8+ T cells 
To study the alloreactive CD8+ T cell response after stimulation with TECs, TECs pre-treated 
with IFNs were used as stimulators to test the IFN-γ production by PHA-activated CD8+ T 
cells. Similarly to the CD4+ T cell responses, TECs alone only induced weak CD8+ T cell 
activation, measured by a low IFN-γ production in the supernatants of T cell/TECs co-
cultures. Blockade of both PD-L1 and PD-L2 on the TECs significantly increased the IFN-γ 
production of CD8+ T cells by 2-3 folds (Fig. 3). In analogy to the CD4+ T cell responses, 
single PD-L1 blocking on TECs increased the IFN-γ production of CD8+ T cells to the same 
magnitude as with the double blocking, and no increase of IFN-γ production was obtained by 
PD-L2 blocking (Fig. 3).  
 
PD-L1 on TECs inhibited the IFN-γ production of alloreactive CD4+ and CD8+ T cells 
Since PHA activates T cells non-specifically and independently of TCR signaling, our results 
may not be completely transferable to alloreactive T cell responses. Thus we repeated these 
experiments by using allogeneic and autologous pre-stimulation of CD4+ and CD8+ T cells. 
Autologously and allogeneically pre-stimulated CD4+ and CD8+ T cells were co-cultured with 
IFN pre-treated TECs of patient 2 (P2 TEC). Since blockade of PD-L2 on TECs did not 
increase the T cell response in the previous experiments (Fig. 2 and 3), only PD-L1 blockade 
was performed. Allogeneic pre-activation of CD4+ T cells with T cell-depleted PBMCs of 
patient 2 induced high amounts of IFN-γ compared to autologous pre-activation of CD4+ T 
cells (Fig. 4A, T cells alone), indicating that the allogeneic pre-stimulation effectively 
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activated CD4+ T cells of the healthy donor. 
 Re-stimulation of these allogeneically or autologously pre-activated CD4+ T cells with 
the TECs of this patient 2 (P2 TEC) could not further increase the IFN-γ secretion. However, 
inhibition of PD-L1 on P2 TEC significantly augmented the IFN-γ production by 
allogeneically and to a much lesser degree also by autologously pre-activated CD4+ T cells. 
As expected, the cytokine response of the allogeneically pre-activated CD4+ T cells was 
significantly higher.  
 The alloreactive CD8+ T cell response showed a similar pattern (Fig. 4B). Pre-
activation of CD8+ T cells by allogeneic CD4-CD8-PBMC of patient 2 induced moderate IFN-
γ production. Inhibition of PD-L1 on P2 TEC dramatically increased the IFN-γ secretion of 
allogeneically pre-activated CD8+ T cells. In contrast, blockade of PD-L1 on P2 TEC only 
slightly enhanced the IFN-γ production of autologously pre-activated CD8+ T cells. In 
conclusion, these data reveal that CD4+ and CD8+ T cells pre-activated with the patient’s 
allogeneic CD4-CD8- PBMCs showed a much stronger cytokine response to P2 TECs than 
autologously pre-activated T cells. Our results suggest that PD-L1 on TECs plays a 
predominant role in inhibiting alloreactive CD4+ and CD8+ T cell responses induced by 
TECs. 
     
Strong induction of PD-L1, PD-L2 and PD-1 mRNAs in human biopsies of kidney allograft 
rejection 
The mRNA expression of PD-L1, PD-L2 and their receptor PD-1 was then investigated in 
renal biopsies of patients with acute kidney transplant rejection (ATR), interstitial 
fibrosis/tubular atrophy (IF/TA) (18) and BK virus nephropathy (BKN) by real-time RT-PCR. 
Compared to control tissues (pretransplant biopsies; living donor n=9, deceased donor n=1), 
PD-L1 mRNA transcript levels were significantly increased only in renal biopsies of patients 
with ATR, but not in biopsy samples with IF/TA or BKN (Fig. 5A). PD-L2 mRNA was 
significantly enhanced in biopsies of patients with ATR or IF/TA (Fig. 5B). In addition, 
biopsies of all patients showing a high PD-L1 mRNA induction had also increased mRNA 
levels of PD-L2 (Pearson, r=0.6480, p=0.0006). PD-1 mRNA was also significantly induced 
in biopsies with ATR, IF/TA and BKN (Fig. 5C).  
 
Patient characteristics and correlation to the PD-L1, PD-L2 and PD-1 mRNA levels 
The relevant clinical parameters including recipient age, gender, creatinine and proteinuria as 
well as histological parameters like scores for tubulitis, interstitial infiltration, chronic lesions 
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and Banff classification at the time of biopsy were extracted from the ERCB-KFB (Table I). 
PD-L1, PD-L2 and PD-1 mRNA revealed no correlation to creatinine and proteinuria levels. 
Possibly the cohort size was too small for such analysis. Since, follow-up data are not 
routinely collected from allograft recipients in the ERCB-KFB, a correlation with the 
response to treatment could not be assessed. However, the expression of PD-L1 was 
significantly increased in patients with vascular rejection (Banff IIA and IIB) compared to 
tubulointerstitial rejection (Banff IA and IB) (Fig. 6A). This was not the case for PD-L2 (data 
not shown). In contrast, the score for tubulitis showed a tendency to be lower in patients with 
vascular rejection (Banff IIA and IIB, Fig. 6B).  
 
PD-L1 and PD-1 localization in human allograft rejection 
We speculated that the increased mRNA expression of PD-1 detected in the biopsies might be 
due to infiltrating lymphocytes and the enhanced PD-L1 mRNA expression would be 
expected on TECs as well as on infiltrating leukocytes. To localize PD-L1 and PD-1 we 
performed immunohistochemistry on a series of archival allograft biopsies and on two renal 
allograft nephrectomies with severe acute vascular rejection in addition to signs of chronic 
injury (IF/TA, n=2). The allograft biopsies included acute interstitial rejection (Banff IB) and 
biopsies without acute rejection with well preserved tissue architecture (n=3). In allograft 
nephrectomies, surface expression of PD-L1 was found on infiltrating cells in the 
tubulointerstitium which displayed dendritic cell morphology (Fig. 7A) and on tubular 
epithelial cells (Fig. 7A and 7C). Pre-incubation of the anti PD-L1 antibody with its peptide 
completely abolished the positive PD-L1 staining (Fig. 7B). PD-1 was expressed by 





The wide distribution of PD-L1 and PD-L2 in lymphoid and parenchymal tissues (3, 4) 
suggests a broad regulatory function on various immune responses, including autoimmunity 
and self tolerance (13). Recent studies indicated an important role for the PD-1/PD-L pathway 
for allograft rejection and tolerance in experimental models (11, 19). Here, we demonstrated 
that the co-inhibitory molecule PD-L1 expressed on human renal TECs suppresses human 
alloreactive T cell responses and is associated with acute kidney allograft rejection. 
 
Earlier studies showed that CD4+ T cells do not respond to allogeneic TECs pre-treated with 
IFN-γ. This was in part due to the lack of co-stimulation, especially the absence of B7.1 
molecules on TECs (6, 20). However, our study now reveals that the existence of the PD-
1/PD-L1 co-inhibitory pathway plays a crucial role for the unresponsiveness of alloreactive T 
cells towards renal TECs, since inhibition of PD-L1 on TECs strongly augmented the CD4+ 
and CD8+ T cell responses. An increased alloreactive CD8+ T cell response could only be 
measured in terms of IFN-γ production, whereas the same CD8+ T cells were not able to lyse 
allogeneic renal TECs even though they demonstrated a strong CTL activity to Jurkat cells 
(data not shown). These results indicate that human TECs are highly resistant to the attack of 
alloreactive CTLs in vitro. The limited co-stimulatory molecule expression on TECs, 
including the lack of strong B7/CD28 co-stimulation, could at least partially explain this 
phenomenon. 
 
Our results demonstrated that IFN-β and IFN-γ play a critical role in the upregulation of the 
PD-L1 and PD-L2 expression on TECs in vitro. Obata et al. showed that the expression of 
IFN-γ mRNA was strongly increased in acute and chronic human renal allograft biopsies (21). 
It is therefore possible that, during local inflammation, IFN-β production as part of the innate 
immune response and IFN-γ secretion from infiltrating alloreactive T cells are both 
responsible for the in vivo increase of PD-L1 (and PD-L2) expression on renal 
tubulointerstitial tissues as observed in our study. This is consistent with the observation that 
the expression of PD-1 is absent in healthy kidneys without inflammation (22). The 
expression of PD-1 in allograft biopsies with acute rejection indicates the presence of 
activated T cells within the inflamed kidneys. Importantly, more intense tubulitis seems to be 
associated with lower PD-L1 expression during tubulointerstitial rejection, whereas the 
opposite was observed for vascular rejections. This may suggest that during more severe acute 
vascular rejections the tubulointerstitium is partially protected by the expression of PD-L1, 
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whereas this is not the case for the vascular endothelium which does not express PD-L1 (Fig. 
7A). These results complement previous observations of high PD-L1 expression on renal 
tubules in other immune-mediated human renal diseases, including diffuse proliferative lupus 
nephritis, IgA nephropathy and tubulointerstitial nephritis (9, 22). Therefore there is 
increasing evidence that the PD-1/PD-L1 pathway is involved in immune-mediated human 
renal diseases and especially in acute kidney transplant rejection.  
 
Although PD-L2 upregulation was observed in our biopsy samples and on IFN-stimulated 
TECs, it does not seem to play an inhibitory role in human kidney transplantation. There was 
no correlation to histological parameters and in vitro blockade of PD-L2 on TECs was not 
effective. This was not due to the failure of the anti-human PD-L2 mAb included in this study 
because the same clone of mAb was successfully used to inhibit PD-L2 activity of T cell 
stimulator cells by others (23). Several studies suggested distinct roles of PD-L1 and PD-L2 
in regulating T cell activity. Tanaka et al. indicated that blockade of PD-L1 but not PD-L2 
accelerated cardiac allograft rejection associated with an increased frequency of IFN-γ 
producing alloreactive T cells and the expansion of effector CD8+ T cells (24). Consistent 
with this observation, Sandner et al. showed that inhibition of PD-L1 but not PD-L2 enhanced 
CD4+ T cell activation in a skin graft model (12). The function of PD-L2 may also depend on 
the location of immune responses. Habicht et al. demonstrated that in the host lymphoid 
organs as opposed to parenchymal tissue the in vivo activation of both alloreactive CD4+ and 
CD8+ T cells was primarily mediated by PD-L2. Furthermore, the increased proliferation of 
CD8+ T cells after in vivo blockade of PD-L2 was dependent on CD28-mediated co-
stimulation signal (25), which does not play a role for TECs, that do not express B7 
molecules.  
 
Experimental models of heart (11, 19) and corneal allografts (26) showed a critical and 
protective role of the PD-1/PD-L1 pathway in transplantation. Although the increase of PD-
L1 on donor TECs is not sufficient to completely prevent acute allograft rejection, our results 
suggest a protective mechanism of parenchymal tissues to mitigate alloreactive human T cell 
responses and tissue injury via PD-1/PD-L1 co-inhibitory pathway. Strategies to selectively 
enhance PD-L1 expression on TECs as well as on professional APC might be therapeutically 







Figure 1: Flow cytometric analysis of PD-L1/2 and MHC class I/II on human primary 
TECs. (A, B) Human primary TECs were stained with mAb for PD-L1 and PD-L2 expression 
after 48 h stimulation with IFN-β or IFN-γ at different doses (A) as well as after treatment 
with both cytokines together (B) and compared to untreated controls. (C) MHC class I and 
MHC class II expression was determined with Ab against HLA-ABC and HLA-DR, 





Figure 2: Proliferation and IFN-γ production of CD4+ T cells after stimulation with 
human primary TECs pre-treated with IFNs. CD4+ T cells activated with PHA were co-
cultured with IFN-pre-treated TECs of patient 1 (P1 TEC) or of patient 2 (P2 TEC) (2x104 
cells/well) at the indicated responder/stimulator ratios of 20, 10, 5 and 2.5:1. Before addition 
of TECs to T cells, TECs were incubated for 1 h with αPD-L1 and/or αPD-L2 Ab or isotype 
control. After 72 h of co-culture the proliferation (A, B) and the IFN-γ production (C) of 
CD4+ T cells was determined. The results represent mean values ± SD of triplicate wells and 
are representative for CD4+ T cell responses of 4 different donors which gave similar results. 





Figure 3: IFN-γ production of CD8+ T cells after stimulation with human primary TECs 
re-treated with IFNs. CD8+ T cells activated with PHA were co-cultured with IFN-pre-p
treated TECs of patient 1 (P1 TEC) (1x104 cells/well) at the responder/stimulator ratio of 
30:1. Before addition of TECs to CD8+ T cells, TECs were incubated with αPD-L1 and/or 
αPD-L2 Ab or isotype control. After 48 h of co-culture the IFN-γ production of CD8+ T cells 
was determined. The results represent mean values ± SD of triplicate wells and are 
representative for CD8+ T cell responses of 4 different responders which gave similar results. 




Figure 4: IFN-γ production of alloreactive CD4+ and CD8+ T cells after stimulation with 
human primary TECs pre-treated with IFNs. CD4+ and CD8+ T cells were pre-activated 
with allogeneic (patient 2) or autologous T cell-depleted PBMCs and were co-cultured with 
IFN-pre-treated TECs of patient 2 (P2 TEC) at a responder/stimulator ratio of 20 and 30 for 
the CD4+ T cells and the CD8+ T cells, respectively. Before addition of TECs to T cells, TECs 
were incubated for 1 h with αPD-L1 Ab or isotype control. After 72 h (A) or 48 h (B) of co-
culture the IFN-γ production of CD4+ T cells (A) and CD8+ T cells (B) was determined. 





Figure 5: PD-L1, PD-L2 and PD-1 mRNA expression in human renal biopsies. (A) Renal 
biopsies from patients with acute transplant rejection (ATR, n=12), interstitial fibrosis and 
tubular atrophy (IF/TA n=11) and BK virus nephropathy (BKN, n=7) were compared to pre-
transplant tissue samples (control, n=10) for the mRNA expression of PD-L1. (B) For PD-L2 
9 samples of ATR, 8 of IF/TA, 7 of BKN and 10 of controls and (C) for PD-1 8 of ATR, 8 of 
IF/TA, 7 of BKN and 8 of controls were analyzed. mRNA expression of PD-L1, PD-L2 and 
PD-1 were normalized to the expression of 18S rRNA and the fold inductions of the target 
genes in the above mentioned entities were calculated compared to the control tissue (=1). 
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PD-1 mRNA expression was not detectable in some samples which are shown below the x-
axis. *p<0.05, **p<0.001, ***p<0.0001 when compared with controls (Mann-Whitney-U 






igure 6: PD-L1 mRNA induction is pronounced in vascular allograft rejection. (A) F
Relation of PD-L1 induction between patients suffering from acute tubulointerstitial rejection 
(Banff IA/IB) and vascular rejection (Banff IIA/IIB). (B) Comparison of the tubulitis score 
between tubulointerstitial rejection (Banff IA/IB) and vascular rejection (Banff IIA/IIB) 




Figure 7: Immunohistochemistry of PD-L1 and PD-1 expression on allograft biopsies. 
(A) In allograft nephrectomies PD-L1 was expressed by large cells with a dendritic cell 
morphology in the tubulointerstitium (arrowheads) as well as by some tubular epithelial cells 
(arrows). (B) Pre-incubation of the anti- PD-L1 Ab with the peptide used for immunization 
completely abolished the positive staining demonstrating specificity of the staining. (C) 
Prominent expression of PD-L1 by tubular epithelial cells (arrows). (D) PD-1 positive cells 
resemble small lymphocytes (some are indicated by arrowheads), which were present in foci 
of smaller and larger accumulations of infiltrating cells. (original magnifications: x100 A, B; 
x200 C, D)      
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Table I: Clinical and histological characteristics of biopsies from patients with acute transplant 
rejection, interstitial fibrosis/tubular atrophy, BK virus nephropathy and control subjects 
analyzed by real-time RT-PCR.  
 
Age Creatinine Proteinuria Grade of damage Biopsy group 
(yr) 
Gender Graft 
(µmol/l) (g/d) Ci/ct int if tub inf 
Banff 
Acute transplant 
rejection          
ATR1 47 M dcd 424 n.a. 2 3 2-3 IIB 
ATR2 71 F dcd 455 0.5 2 1-2 0 IIA 
ATR3 47 M dcd 240 0.1 0 2 2 IIA 
ATR4 49 M dcd 720 n.a. 0 2 1 IIA 
ATR5 61 F dcd 456 n.a. 0 2 3 IB 
ATR6 54 F dcd 909 n.a. 0 2 2 IA 
ATR7 49 M dcd 177 0.18 2 n.a. n.a. IA 
ATR8 47 M dcd 440 0.3 0-1 2 3 IB 
ATR9 65 M dcd 488 n.a. 2 2 2 IIA 
ATR10 61 F dcd 637 n.a. 1 2 1 IIB 
ATR11 43 M dcd 908 n.a. 0 2 1 IIB 
ATR12 49 M n.a. 203 n.a. 0 1 2 IIA 
Interstitial fibrosis/          
Tubular atrophy          
IF/TA1 46 M dcd 174 n.a. 1 0-1 0  
IF/TA2 60 F n.a. 220 0.325 1 0-1 0  
IF/TA3 23 F liv 188 n.a. 1 0-1 0  
IF/TA4 66 F dcd 120 2 1-2 0 0  
IF/TA5 32 F dcd 234 n.a. 3 1 0  
IF/TA6 52 n.a. n.a. 548 1.82 2 0-1 0  
IF/TA7 37 M n.a. 884 7 2 0 0  
IF/TA8 32 M dcd 171 1.5 1-2 0-1 0  
IF/TA9 34 F dcd 495 0.8 3 0-1 0  
IF/TA10 67 M dcd 294 0.2 1 0-1 0  
IF/TA11 66 M dcd 225 5 1 0-1 0  
BK virus nephro-
pathy          
BKN1 37 M dcd 301 n.a. 0-1 2 0  
BKN2 41 M dcd 539 0.4 2 1-2 3  
BKN3 52 F dcd 273 8.3 0 2 2  
BKN4 35 F dcd 528 1.26 2 1 0  
BKN5 57 M dcd 426 n.a. 1 2 2  
BKN6 66 F dcd 320 0 3 1-2 0  
BKN7 40 F dcd 280 2.3 2 1-2 0-1  
Control subjects          
C1 35 F liv <97 <0.2     
C2 39 M liv <97 <0.2     
C3 55 F liv <97 <0.2     
C4 41 M liv <97 <0.2     
C5 61 M liv <97 <0.2     
C6 58 F liv <97 <0.2     
C7 27 M liv <97 <0.2     
C8 n.a. n.a. dcd <97 <0.2     
C9 54 F liv <97 <0.2     
C10 61 F liv <97 <0.2     
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ci/ct: chronic interstitial fibrosis and chronic tubular atrophy; int inf: interstitial 
infiltration/inflammation; tub inf: tubular infiltration/tubulitis; Grade of damage/score 
0: no or minimal, <5% for ci/ct and < 10% for int inf; 1: mild (<25%); 2: moderate 
<50%; 3: severe > 50%; for tub inf 0: no cells/tubular cross section; 1: 1 to 4 
cells/tubular cross section; 2: 5 to 10 cells/tubular cross section; 3: >10 cells/tubular 
cross section; Banff IA/B: tubulointerstitial rejection; IIA/B-vascular rejection; n.a: 
not available; dcd: deceased donor; liv: living donor 
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